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To be successful as pathogens, the capsids of nonenveloped viruses must 
balance two opposing roles:  they must be structurally robust in order to protect the 
encapsulated genome from environmental insults outside of the host cell, yet 
metastable to allow release of the viral genome upon infection. 
A goal of these studies was to further characterize the antibody response 
directed against canine parvovirus (CPV), and to understand the interplay between 
receptor and antibody binding to the capsid.  Another goal was to understand the 
conformational changes that occur in the structure of the CPV capsid during infection, 
and to understand the biological significance of these changes. 
A panel of eight antibodies directed against the virus were shown to be 
neutralizing as intact immunoglobulin G proteins (IgGs).  However the fragment 
antigen binding domains (Fabs) of these IgGs differed greatly in their ability to 
neutralize CPV.  These eight Fabs compete for receptor binding on the surface of 
cells, and compete with soluble receptor in solution, although the neutralizing Fabs 
competed for binding at significantly lower Fab to capsid ratios.  Structural analysis of 
those Fabs demonstrated that most accessible areas of the capsid were able to generate 
an immune response and participate in antibody binding.   
CPV is a highly stable virus, and many harsh conditions do not cause large 
structural changes in the virus.  By biochemical and biophysical assays presented here, 
the viral capsid was unchanged until pH 4 and is thermally stable to temperatures of 
70°C.  Conditions that the virus would encounter during infection, such as low pH and 
 calcium removal, did not have direct structural effects on the CPV capsid. 
Furthermore, transferrin receptor or antibody binding did not cause detectable changes 
to the capsid structure. 
These studies show that CPV is an extremely robust pathogen, due to its highly 
stable capsid.  The capsid has clearly evolved to persist in harsh environmental 
conditions outside of the cell, and infect in the presence of circulating antibodies. 
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Introduction 
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1.1 Parvovirus characteristics. 
Canine parvovirus (CPV) belongs to the Parvoviridae family, the characteristic 
traits of which are a small nonenveloped icosahedral capsid, and a DNA genome of 
roughly 5kb which is linear, self priming, and single-stranded.  Sixty copies of several 
isoforms of the same capsid protein encase this genome, to form a capsid of around 25 
nm diameter.  Transcription will not occur off of the ssDNA, and therefore 
parvoviruses likely wait for a cell to begin S-phase to allow DNA fill-in so that 
replication and transcription can occur (47, 124, 187). 
 
1.2 CPV emergence and pathogenesis. 
Canine parvovirus is a relatively new pathogen of canines, first detected in 
1978 and having emerged ~4-10 years earlier (128, 157).  CPV most likely evolved 
from a closely related virus of cats, feline panleukopenia virus (FPV) (67, 123, 124, 
127, 176).   CPV generally infects naïve dogs and newborn puppies, and causes 
enteritis or myocarditis in infected animals (134).  The frequency of symptomatic 
infection is believed to be small, since reactive sera is recovered from many animals 
that have not presented symptoms of CPV infection.  The natural course of 
transmission is through the fecal-oral route, and CPV is believed to initially infect 
epithelial or immune cells of the tonsils.  CPV uses the transferrin receptor (TfR) to 
bind and enter cells, and as mentioned, requires cells to be in S-phase in order to 
replicate its DNA (122, 139, 140).  This restricts susceptible cells to those that are 
actively dividing, and those that show upregulation of TfR expression.  Infection of 
the tonsils results in viral sheding into the lymphatics and blood, and the establishment 
of a viremia that then infects other lymph nodes, other immune tissues including the 
thymus and bone marrow, and eventually the crypt cells of the small intestinal villi 
(183).  In young puppies, infection of the rapidly dividing cells of the myocardium 
2 
 
 
 
3 
 
leads to myocarditis.  Enteric symptoms are the result of infection of crypt cells, which 
cause a loss of the intestinal epithelium and intestinal integrity, and leakage of large 
amounts of sera into the intestinal contents.  Virus is shed in this diarrhea in titers as 
high as 109 infectious doses per ml.  Persistent infection is not seen in CPV, and most 
infections are now seen in young puppies that have lost maternal antibody protection 
around 8 to 12 weeks of age (125, 134). 
 
1.3 Splicing of primary transcripts and capsid composition. 
The currently recognized capsid proteins of CPV, termed Viral Protein 1 and 2 
(VP1 and VP2), are generated from the same primary transcript, which is transcribed 
from the promoter at map unit 38 of the CPV genome (36, 133).  Alternate splicing of 
this transcript leads to different mRNAs corresponding to VP1 or VP2, and splicing 
efficiency of VP1 results in approximately 25% of the capsid protein in an infected 
cell to be VP1 and the remaining to be VP2 (78). These protein ratios are not reflected 
in the composition of the capsid, where 5-6 of the 60 copies of capsid protein are VP1, 
and which indicates that factors other protein abundance may dictate the relative 
protein ratios within the CPV capsid (174).  VP1 (767 residues, 80.3 kda) contains the 
VP2 sequence (584 residues, 64.7 kda) plus an additional 143 amino acids on its N-
terminus, termed the VP1 unique region (VP1ur).  Within the VP1ur is a 
phospholipase A2 (PLA2) domain and several groups of basic amino acids that can act 
as nuclear localization sequences (NLS), and both motifs are critical for infection 
(193, 203)(Figure 1.1a).  VP2 expressed alone can form virus-like particles (VLPs), 
implying that VP2 contains all the necessary information for capsid assembly (72, 
151).  These VP2-only capsids are able to package DNA, implying that there are no 
special sequences within VP1 necessary for DNA packaging (188).  It is not known 
how VP1 and VP2 are arrayed within the capsid.  Research within the related 
 
 
Figure 1.1a. 
Transcriptional layout of CPV-2 and features of VP1 and VP2.  Transcription from the 
promoter at P38 leads to the capsid protein precursor mRNA.  Alternative splicing 
results in mRNAs for either VP1 or VP2.  Alternative splicing of the VP2 mRNA 
removes the start codon of VP1, and translation of VP2 starts at a second start codon 
~400 nt downstream.  A schematic diagram of VP1 and VP2 are shown.  VP1 contains 
an additional 143 residues that contain a PLA2 domain and NLS. 
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parvovirus H1 suggests that VP1 may be clustered within the capsid, since chemical 
cross-linking results in a higher than expect proportion of VP1-VP1 linkages (120). 
 
1.4 Capsid structure of CPV. 
The atomic structures have been solved for CPV, FPV, and related mutants, 
and VP1 and VP2 contain extensive secondary structure (Figure 1.1b).  VP1 and VP2 
also share the same core structural feature, an anti-parallel beta (β) barrel motif (3, 61, 
187, 202) (Figure 1.2a).  This motif is present in many other nonenveloped viruses, 
including the well-studied picornaviridae family, although CPV contains two 
additional β-strands (150). 
In this beta barrel, β-strands BIDG (plus the extra strands βA and βB) line the 
interior of the capsid, while the CHEF strands fill volume between the interior and 
exterior surfaces.  The exterior surface of the capsid is composed of the loops that 
connect the strands of the β-barrel.  Some of these loops are quite large and complex, 
with the GH loop being the largest at 221 amino acids (187).  These loops are 
responsible for many of the functions associated with viral functions, host interactions 
and cell infection, such as receptor and antibody binding (71, 160, 169, 179).  
CPV is one of the smallest viruses, with the intact capsid having a diameter of 
260Å at its widest point.  The 60 VP1 and VP2 monomers that comprise the capsid 
show a T=1 icosahedral symmetry (Figure 1.2b)(187).  The symmetry elements are six 
5-fold axes of symmetry, fifteen 2-fold axes of symmetry, and ten 3-fold axes of 
symmetry (these numbers are doubled if you count the structures on either side of the 
axis, rather than the axis itself).  Analysis of the crystal structure shows that the GH 
loops from adjacent monomers around the 3-fold axis inter-digitate to form a large 
raised region over the 3-fold axis.  The calculated free energy of formation of the 3- 
fold axis is large (-201 kJ per mol subunit), indicating that this structure is much 
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Figure 1.1b. 
Secondary structure representation of the VP2 capsid structure.  Loops are colored 
based on structural features.  These colors are consistent with Figure 1.2a.  The core β-
barrel is colored in red.  The surface loop 1 (BC strands) is colored in orange, loop 2 
(EF strands) is colored in blue, and loop 3-4 (GH strands) are colored in purple.  The 
beta ribbon forming the 5-fold pore (DE) is colored in green. 
 
7 
 
 
 
8 
 
 
 
Figure 1.2a. 
Three dimensional structure of the VP2 capsid protein structure.  The alpha carbon 
backbone is rendered as a cartoon and the structure is colored according to its different 
features.  The core β-barrel is colored in red.  The surface loop 1 (BC strands) is 
colored in orange, loop 2 (EF strands) is colored in blue, and loop 3-4 (GH strands) 
are colored in purple.  The beta ribbon forming the 5-fold pore (DE) is colored in 
green. 
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Figure 1.2b. 
The assembled capsid structure of CPV.  The capsid is surface rendered, and three 
VP2 monomers are differentially colored to display their orientation in the capsid.  
The asymmetric unit is overlaid onto the capsid.  The 5-fold, 3-fold, and 2-fold axes of 
symmetry are indicated by a pentagon, triangle, and oval, respectively. 
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more stable than the pentamers (-75 kJ per mol subunit) or dimers (-37 kJ per mol 
subunit) (202).  This raised region around the 3-fold axis is termed the 3-fold spike 
and is a prominent structural feature of the viral capsid, measuring 70Å wide and 22Å 
high (1). 
Another major feature of the capsid of CPV is the ~10 Å wide pore that are 
present at each 5-fold axis of symmetry that extends to the interior of the capsid.  This 
pore is formed by β ribbons of the DE loops of each of the 5 surrounding monomers 
which form a cylinder.  It is believed that the N-termini of the VP2 capsid proteins are 
externalized through these pores, and the 5’-end of the viral DNA is believed to be left 
exposed from the capsid through one pore after it is packaged (202).  A glycine-rich 
region between resides 22 and 39 (VP2 numbering) is shared by both VP1 and VP2, 
and this region is believed to reside within the pore for ~11 of the VP2s in full (but not 
empty) capsids (2, 45, 202).  Occupancy of the 5-fold pore by this stretch of glycines 
and other residues with small side-chains causes only minor steric clashes with the 
wall of the pore.  However, externalization of the N-terminal ~20 amino acids would 
require an enlargement of the pore, as the bulky side chains in that sequence would 
cause significant clashes as they pass through the pore (202).  The actual diameter of 
this pore in solution is therefore not known, but it is assumed that the β-strands 
comprising the pore and the surrounding residues are dynamic and able to separate and 
allow the pore to expand.  In accordance with this hypothesis, there are cavities 
surrounding the 5-fold pore that may be compressed to allow room for the expansion 
of the pore (28).  The compression of cavities in viral proteins during the infectious 
cycle has been demonstrated in other viruses (29, 33). 
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1.5 VP1 unique region. 
1.5a Phosopholipase A2 (PLA2) domain. 
Sequence analysis of most parvoviruses shows a series of conserved residues 
in the VP1ur (residues 33-91 in CPV).  These residues constitute a functional PLA2 
enzyme, which is in the same class as the calcium dependant secretory PLA2s (203).  
Phospholipases are classified based on the bond they hydrolyze, and PLA2 enzymes 
hydrolyze the ester bonds at the sn-2 position of phospholipids (201).  PLA2 is further 
classified into more than ten groups based on their enzymatic and structural 
characteristics, with the parvovirus PLA2s belonging to group XIII (26).  The 
parvovirus PLA2s differ greatly in their specific activity, but all have similar substrate 
specificities and pH sensitivities (178).  In addition, all of these parvovirus PLA2s 
require millimolar calcium concentrations to function.   
The active site of parvovirus PLA2 consists of a histidine-aspartic acid (HD) 
dyad, which is highly conserved among the different viruses (203).  The unprotonated 
His residue polarizes a water molecule, which then attacks the carbonyl bond at the sn-
2 position of the phospholipid (178).  PLA2 of parvoviruses are most active at pH 6-7 
(203).  This is most likely a result of deprotonation of the histadine residue in the HD 
dyad.  This deprotonation is necessary to coordinate the water molecule that is 
responsible for the nucleophilic cleavage of the phosopholipid.  The PLA2 of CPV is 
believed to be similar to most secretory phospholipases that do not dissociate from the 
membrane after hydrolysis, and instead move along the membrane to cleave the next 
phospholipid (201).  All parvovirus PLA2s studied so far are able to bind efficiently to 
the zwitterionic phosphatidylcholine lipids that make up the majority of the external 
leaflet of the plasma membrane, and also are the predominant lipid in the internal 
leaflet of endosomes (26).  
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PLA2 is critical for infection, as point mutants that render PLA2 inactivate 
render the virus non-infectious, and these mutant virions are seen to accumulate in 
endosomes near the perinuclear regions of cells similar to wild type particle (56, 59, 
203).  This indicates that PLA2 deficient particles are able to bind, enter, and traffic 
through cells similar to wildtype particles.  The lack of infectivity is thought to be a 
failure of virions to escape from these perinuclear endosomes or lysosomes, and the 
mutant virions are subsequently degraded.  Also, infection of CPV in the presence of 
PLA2 inhibitors reduced infection, although the effect of these inhibitors on cell 
division was not examined and whether they have direct effects on the viral infection 
is not clear (171).  In the closely related parvovirus minute virus of mice (MVM), a 
mutant PLA2 deficit was complemented in trans by addition of bee venom PLA2, 
indicating that covalent linkage of the capsids and PLA2 are not necessary for 
infection (56).  Since this class of phospholipase requires levels of calcium that are 
approximately 1000-fold higher than the cytoplasm, it is likely that this enzyme acts in 
the extracellular space or in organelles with relatively high calcium levels (178).  The 
CPV capsid coordinates 120 or 180 calcium ions (depending on the variant) and it is 
possible that those ions are released in the endosome and enhance enzyme activity.  
The VP1 encoded PLA2 domain is not accessible on the surface of the virus before 
infection, and is enzymatically inactive prior to externalization (203).  During 
infection, this domain becomes accessible, and this externalization is believed to be a 
critical point in infection (171). 
 
1.5b Nuclear localization signals (NLS). 
Amino acid residues 4-13 of VP1 act as a functional NLS for the CPV particle 
(188, 192).  When synthetic peptides corresponding to these residues were attached to 
fluorescently labeled bovine serum albumin, the localization of the albumin was 
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changed from cytoplasmic to nuclear.  Furthermore it was shown that this process of 
nuclear localization was receptor mediated and energy dependant, as either excess 
unconjugated peptides or energy poisons blocked this process (192).  Finally, point 
mutations within this sequence resulted in virions that were less infectious (196).  
Additional sequences between residues 109-130 of VP1 also resemble NLS, but their 
significance is less well understood, since peptide-albumin conjugates of these 
residues do not traffic to the nucleus (94, 192).  The VP1ur that contains this NLS is 
believed to be contained within the capsid and becomes externalized during infection 
(195).  To date however, there is no clear mechanistic understanding as to how these 
NLS sequences become accessible or engaged by the cellular transport machinery 
(47).  Presumably, exposure of this NLS would engage the karyopherin transport 
machinery and result in trafficking of the particle through the nuclear pore, allowing 
the viral genome to gain access to the host polymerases that are necessary for viral 
transcription. 
 
1.6 Localization of N-termini of VP1 and VP2. 
The atomic resolution structures of all parvoviruses solved to date do not show 
the N-termini of either the VP1 or VP2.  For CPV, the protein is resolved started at 
amino acid 38 (VP2 numbering) (187).  The inability to detect significant electron 
density associated with the N-terminus of VP1 or VP2 indicates that this area of the 
capsid is disordered in the crystal structure, and is likely dynamic in solution.  In most 
crystal structures of full capsids, weak electron density is seen in the pore at the 5-fold 
axis of symmetry and that is believed to correspond to the Gly-rich sequence near the 
N-terminus (presumably of VP2).  Based on electron density calculations in the 2.9 Å 
structure of DNA containing capsids, at least 60 percent of the pores are filled with 
polypeptides from VP2 (202).  Since the pore is large enough to accommodate a single 
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polypeptide chain, it is believed that these VP2 N-termini alternate in their occupancy 
of the pore.  There are however, no direct measurements of the rates of externalization 
of these N-termini reported. 
The extra-capsid accessibility of the N-terminus VP2 appears to be important 
for successful nuclear export of the assembled full capsids of MVM.  Normal infection 
produces a proportion of capsids that lack DNA, and in those empty capsids the N-
terminus of VP2 is sequestered within the capsid.  This N-terminus is accessible in full 
capsids with packaged DNA, implying that the packaging process results in the 
extrusion of these N-termini, or alternatively that in empty particles the N-termini 
withdraw into the particle.  Since the capsid may be packaged under pressure, DNA 
packaging may force some of N-termini to an exterior position (45, 46).  Within the N-
terminus of VP2 is a nuclear export signal (NES).  For MVM, when that peptide is 
synthesized and conjugated to fluorescently labeled bovine serum albumin it can result 
in trafficking of the albumin out of the nucleus (101).  Full MVM particles that lack 
this NES remain localized in the nucleus very late in infection (101).  MVM contains 
several serine residues in this NES, and phosphorylation of these residues is important 
for export.  It is believed that the CRM-1 export pathway is important for this process, 
but the exact interactions between this molecule and the capsid have not been 
demonstrated (95, 101). 
The N-terminus of VP1 is also not resolved in the atomic resolution structure 
of CPV (202).  This is not surprising as VP1 represents 10% of the capsid protein and 
would not be able to fully occupy any of the symmetry positions on the capsid.  Since 
60-fold icosahedral averaging was used to solve the crystal structure of CPV, this 
asymmetrically distributed electron density would be averaged out when solving the 
structure.  Attempts at producing VP1-only particles have not been successful, as 
those particles do not assemble (151).  The N-terminus of VP1 is not accessible in 
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newly formed virions of either full or empty capsids, as determined by probing with 
VP1-specific antibodies against the N-terminus (195).  The PLA2 domain within the 
VP1ur is also not enzymatically active, indicating that the PLA2 is sequestered from 
its substrate, does not have Ca2+ required for its activity, or is in a form that renders it 
inactive (171).  During infection or heating in vitro, this N-terminus becomes 
accessible to VP1 antibodies (195).  There is however some debate as to whether 
VP1ur occupies an internal position within the capsid and this may differ between 
viruses.  In the related parvovirus B19, the VP1ur is initially not accessible to 
antibodies, but after mild treatments capsids can be immunoprecipitated by polyclonal 
sera against the N-terminus (147).  Other studies however, have shown that VP1 N-
terminus can be immunoprecipitated, and recombinant B19 virions that have either 
lysozyme or GFP added to their N-termini are either enzymatically active, or can be 
immunoprecipitated with antibodies against GFP, respectively (148, 110).  If the N-
terminus of VP1 of B19 is normally exposed, it is unclear whether this is an exception 
to the parvovirus family or a more common trait.  A possibility remains that the N-
terminus of VP1 is also external to the capsid but in a denatured form that is not 
reactive to antibodies, or may be on the outside of the capsid but be sequestered in the 
canyon which lies directly around the 5-fold axis and therefore is sequestered from 
antibody binding and PLA2 substrate. 
 
1.7 Sialic acid and lipid binding. 
CPV binds to sialic acid using structures near the two fold axis of symmetry, 
most notable Arg 377, Glu 396, and 397 Arg (179, 10).  The virus appears to 
preferentially bind to sialic acid of the N-glycolyl neuraminic acid form (179).  
However, the role of sialic acid binding in infection remains unclear.  Treatment of 
cells with neuraminidase, which removes the sialic acids, delays the kinetics of 
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binding, but does not prevent infection (179).  Furthermore, mutant viruses that are not 
able to bind to sialic acid are not reduced in their infectivity, and cells that express 
only N-glycolyl neuraminic acid but not transferrin receptor are not permissive for 
infection (10, 194).  It is therefore believed that sialic acid serves as a viral attachment 
factor for cells.  Sialic acid binding may however be important for productive binding 
and entry during in vivo infection of canines.  CPV has been reported to interact with 
sphingomyelin and other phosphoinositides, and lipids may co-purify with the virus 
(117, 171).  It is not clear what effect this binding has on the infectious life cycle of 
the virus. 
 
1.8 Transferrin Receptor. 
CPV uses TfR for binding and uptake into cells (122).  CPV cannot bind or 
enter Chinese hamster ovary (CHO) cells that either express the hamster TfR, or that 
do not express any TfR (the TRVb cell line), but expression of feline or canine TfRs in 
these cells allows binding and infection.  Addition of a polyclonal anti-TfR anti-sera to 
the TRVb cells expressing feline TfR before addition of virus inhibits binding and 
uptake.  This sera also inhibits binding and uptake of viruses to HeLa cells that 
normally express human TfR (122).  Microinjection of a monoclonal antibody against 
the TfR cytoplasmic tail prevents infection. Finally the virus has been shown to bind 
directly to the purified TfR ectodomain in biochemical assays (118). 
The TfR is a homodimeric type II membrane protein that contains several 
functional regions, the cytoplasmic, transmembrane sequences, a stalk that raises the 
receptor above the membrane, and an ectodomain that contains 3 smaller domains, the 
helical, protease-like, and apical domains.  A soluble portion of the ectodomain (sTfR) 
can be generated by treatment of cells with trypsin, which releases the ectodomain 
starting at residue 119, and a similar sTfR can also be produced in vitro by baculovirus 
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expression, expressing a protein corresponding to amino acid residues 119-770 (69, 
90).  The crystal structure of this soluble ectodomin for human TfR has been solved 
(89), and that shares 79% identity with the feline receptor (the feline and canine 
receptor differ by 11%).  Homology modeling can therefore be used to visualize 
important domains on the surface of the feline or canine TfR (Figure 1.3).  Structural 
and biochemical evidence suggests that the receptor is always present as a dimer on 
the surface of cells (156).  TfR contains two interchain disulfide bonds, which are not 
necessary for dimerization, and are not included in sTfR (7, 77).  The interface 
between these monomers is localized between the helical domains of the two subunits 
which form an extensive and stable hydrophobic interaction, having a solvent 
inaccessible surface area of 4100Å (89).  Cryo-EM studies of TfR:Tf complexes show 
that Tf binds to areas of the helical and protease-like domain, on the plasma membrane 
proximal side of the receptor (34).  TfR contains significant post-translational 
modifications including disulfide bonds between dimers, and addition of multiple 
glycans.  The human TfR has 3 N-linked glycosylation sites, and glycosylation of 
some of those sites are necessary for correct folding and surface expression. Mutations 
of the human TfR glycosylation sites results in little or no expression of correctly 
folded TfR (24).  The feline TfR has four glycosylation sites and the canine TfR has 
five, with the extra glycosylation site important for discriminating binding between 
CPV and FPV (119).   
 
1.9 Endocytosis of TfR into cells. 
Endocytosis of TfR and transferrin is well characterized, and is among the best 
characterized examples of clathrin-mediated endocytosis (CME).  TfR controls iron 
homeostasis in the cell through binding and uptake of its natural ligand, iron-loaded 
 
 
Figure 1.3. 
Homology structure model of the dimeric feline transferrin receptor soluble 
ectodomain, based on the solved human TfR crystal structure.  The stalk, 
transmembrane, and cytoplasmic domain are included to orient the ecotdomain with 
respect to the plasma membrane, and are colored orange.  The helical domain, 
protease-like domain, and apical domain are colored green, blue, and red respectively. 
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transferrin (Tf), which bivalently binds iron (54).   Uptake of TfR is a constitutive 
process in the cell, and binding of ligands are not necessary to induce endocytosis 
(81).  The process of CME itself is complex, with a number of accessory proteins 
playing a role in cargo sorting and internalization (161).  Endocytosis begins with 
clustering of TfR into clathrin coated pits, due to the accumulation of cytosolic 
proteins under the plasma membrane, one protein of which is clathrin (54).  Within the 
cytoplasmic tail of TfR is the YTRF domain, which binds the medium chain of adapter 
protein 2 (AP2).  AP2 binds clathrin and oligermization of clathrin forms cage-like 
structures which cause membrane bending and invagination.  The coiled protein 
dynamin is then recruited and forms a collar structure at the proximal side of the 
plasma membrane (83).  This GTPase is responsible for pinching off the vesicle (42). 
The TfR-Tf complex is then delivered to acidic endosomes, and ultimately 
recycles back to the plasma membrane.  The process of TfR-Tf entry and recycling is 
fast, with the iron delivery to low pH endosomes and recycling completed in as little 
as 15 min (175).   The TfR/Tf complex is trafficked to the mildly acidic early 
endosomes that are enriched in the proteins Rab4, Rab5, and EEA-1.  Here the low pH 
causes dissociation of iron from Tf, while remaining associated with TfR.  Most of the 
TfR then accumulates in Rab 11 positive recycling endosomes.  Clustering in these 
endosomes promotes recycling back to the surface, where apo-Tf dissociates back into 
the extracellular space.  Two routes of recycling may be followed, one that is faster 
and those appear to involve the Rab11 recycling compartment, and more direct 
recycling from the early endosome that involves Rab4.  At early times after Tf 
addition to cells, 90% of Tf was associated with Rab4 positive endosomes, and 64% 
was associated with Rab4 endosomes at 30 min after Tf addition (167). A slower 
process occurs through a perinuclear recycling component, in endosomes enriched in 
Rab 11 (158). 
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1.10 Binding, entry, and uncoating of CPV in cells. 
1.10a CPV interactions with TfR. 
Binding of TfR is necessary and most likely sufficient, along with its 
associated endocytic machinery, for viral binding and entry into cells.  Specific 
interactions between CPV and TfR is necessary for infection, as replacement of the 
ectodomain of TfR with other capsid-binding ligands such as an anti-CPV single chain 
antibody fragment of the variable domain (scFv) binds capsids to cells but does not 
mediate infection (69).  It was not determined in this assay whether scFv-Tfr chimeras 
were able to internalize virus.  By flow cytometry, there is no obvious competition 
between CPV and Tf for binding to TfR (70).  Since FPV capsids are unable to bind to 
the canine TfR, chimeras between the canine and feline TfRs can be used to identify 
specific receptor regions or structures that control virus binding.  This approach 
showed that residues in the apical domain of the TfR affect binding to CPV and FPV 
(119).  In addition, changing residue 221 in the TfR from a Leu to Lys resulted in a 
mutant TfR that was able to bind to CPV, but allowed only low levels of infectivity 
(119).  This suggests that successful infection depends on specific interaction between 
CPV and TfR, as other receptors that bind CPV do not allow infection.  However, the 
specific mechanisms that mediate infection through CPV and TfR binding are still not 
understood. 
The interactions between CPV and the soluble feline TfR ectodomain (sfTfR) 
have been analyzed by cryo-electron (cryoEM) microscopy and three dimensional 
image reconstructions.  This co-structure has been solved to 27Å and has allowed for 
the mapping of a sfTfR footprint on the surface of the CPV capsid (63).  sfTfR and 
CPV were shown to have extensive molecular interactions, with approximately 1000 
Å of surface area contact.  It is possible that higher resolution reconstructions would 
result in a smaller footprint on the virus. 
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1.10b Trafficking of CPV within the cell. 
Correct trafficking of CPV capsids within the endosomal system of the host 
cell is thought to be required to ensure infection.  One hypothesis for the high particle 
to infectious unit ratio seen for many animal viruses is a result of incorrect trafficking 
of many particles within the cell (184).  This high particle to infectivity ratio also 
makes it extremely difficult to identify which particle, or which compartment within 
the cell is responsible for infection.  It is also likely that CPV can use multiple 
pathways to infect a cell (65).   
Canine parvovirus begins infection by interacting with TfR on the surface of 
host cells. Similar to TfR bound to Tf, the CPV-TfR complex associates with clathrin 
coated pits, and dominant negative forms of dynamin prevent infection (121).  Binding 
to TfR and entry to the cell through CME enables efficient and rapid entry into cells, 
and the endocytosis within the cells allows the particles to bypass the dense cortical 
actin that lies directly below the plasma membrane.  Other pathways of endocytosis 
may also be used for uptake, and removal of the YTRF motif from the cytoplamic tail 
of TfR reduced the rate of uptake from the cell surface, but did not greatly reduce 
infection, indicating that the virus can still infect cells without using CME (69). 
CPV particles entering the cells initially follow the normal trafficking pattern 
of Tf/TfR, with virus associating with Rab5 positive early endosomes shortly after 
addition of virus.  Unlike the Tf/TfR complexes, which recycle efficiently back to the 
cell surface, the TfR/CPV complexes become associated with Rab7-positive late 
endosomes and lysosomes (21, 171).  Furthermore, microinjected antibodies against 
the cytoplasmic tail of TfR inhibit CPV infection between 2 and 4 hours after 
internalization (122), indicating that the virus must remain bound to TfR for a number 
of hours after binding to the surface of cells.  CPV rapidly traffics to a perinuclear 
region, and can still be detected in that location 10 hours post uptake (172).  The 
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perinuclear vesicles may be recycling endosomes, late endosomes or lysosomes as 
they do not co-localize with a golgi marker TGN-38, or the ER marker PDI (172).  
The virus-containing vesicles are believed to traffic to this perinuclear region along 
microtubules, as treatment of cells with nocodazole prevented this localization (196).  
Trafficking of CPV within the cell is most likely not spatially and temporally 
separated within distinct compartments, and live-cell imaging of the dynamic process 
shows that particles co-localize within various types of endosomes at early times after 
uptake, and do not necessarily proceed in a strictly stepwise manner (Carole Harbison, 
unpublished results). 
How does CPV remain associated with TfR for so long but apparently not 
recycle?  It is thought that clustering of TfR can change the sorting of the receptor and 
its cargo to different pathways.  Uptake of chemically oligermized Tf causes re-
distribution of the cargo to a longer lived recycling endosome or late endosome, slows 
down recycling, and results in increased degradation (102).  It is possible that 
clustering of the dimeric TfR by binding and cross-linking the multivalent causes a 
redistribution of the receptor-capsid complex to late endosomes and lysosomes, and 
this may be a productive step in infection (171).  Thus, although CPV rapidly enters 
cells and seems to traffic to many distinct compartments it is not completely clear 
which compartment or endocytic route is critical for infection. 
 
1.10c Capsid conformational changes associated with infection. 
The parvovirus capsid is a very robust structure, and while it is generally believed that 
a conformational change in the CPV capsid is critical for infection, the nature of any 
structural changes that occur are unknown.  It is presumed that an important 
conformational change required for infection is the release of VP1ur from its internal 
position in the capsid.  Exposure of this domain would expose the active PLA2 
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enzyme that would modify the endosomal membrane, an event that appears required 
for particle escape or to allow re-direction of endosomes, while the exposure of NLS 
signals would allow trafficking to the nucleus.  CPV likely traffics through a late 
endosome or lysosome since low pH is necessary for infection (122, 171).  However, 
it is not clear whether the low pH acts directly to change the structure of the virus, or 
whether this low pH is important in the activation of other cellular events such as 
vesicular trafficking and fusion, or for the activity of low pH-dependent proteases.  
The structures of CPV or FPV at pH 7.5, 6.2 and 5.5 have been solved by X-ray 
diffraction of viral crystals, and only minor changes are seen at low pH.  There is 
however an interplay between low pH and calcium binding (31, 160, 187).  For FPV, 
the flexible loop between residues 360 and 373 becomes increasingly disordered at 
low pH in part due to loss of one of the bound Ca2+ ions, along with the loss of 
hydrogen bonds.  Treatment with EGTA removes all of the Ca2+ ions and this releases 
two loops so that they change positions, and the 360-373 loop is completely 
disordered in the structure (Figure 1.4).  It is not known what physiological effects this 
increased loop flexibility has on CPV or FPV.  This region is in the area where TfR 
and sialic acids bind, and may therefore be important for allowing the capsids to 
disengage from the receptor once inside the cell (63).  Besides this flexible loop, there 
are no other structural changes that have been observed at low pH or calcium levels.   
Low pH may also affect the release of some N-termini of VP1.  Studies of 
MVM capsids show that low pH prevents exposure of VP1ur in an in vitro system 
devoid of any other components (55).  In contrast, for B19 low pH causes 
externalization of VP1ur and capsids can be immunoprecipitated with antibodies 
against this domain (147).  In cells, drugs that prevent acidification of endosomes will 
prevent release of VP1ur as detectable by IFA (99).  Whether these differences are the 
result of experimental differences, or intrinsic differences between viruses is not clear.  
 
 
Figure 1.4. 
Changes in parvovirus capsid flexibility and calcium binding at low pH and addition 
of EGTA.  FPV at pH 7.5 coordinates three Ca+2 ions.  Lowering the pH to 6.5 causes 
loss of secondary structure in the 361-374 loop, and displacement of one Ca+2 ion.  
Removal of the remaining Ca+2 ions by EGTA treatment causes the 36-374 loop to be 
disordered.  Coordinated Ca+2 ions are indicated by red circles. 
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The effect of low pH on VP1ur exposure is difficult to interpret in terms of the atomic 
resolution structure of CPV, since the 5-fold pore of CPV is not expanded at low pH, 
and the temperature factor is not greatly changed, indicating that this area may not be 
more flexible at lower pH.  Also, VP1ur exposure is not the only critical step in 
infection.  Particles that were heated to expose VP1ur and then added to cells whose 
endosomal pH was raised by treatment with Bafilomyacin A1 were not infectious.  
Also CPV particles that were treated with low pH and then microinjected into cells 
were not infectious.  These results indicates that other steps in viral entry besides 
VP1ur exposure require low pH (171). 
Low pH may be important for activation of low pH proteases in late 
endosomes and lysosomes.  All proteases examined so far will convert VP2 to VP3 in 
vitro, and this cleavage is also seen during infection of cells (37, 197).  It is believed 
that proteolysis of VP2 is an essential precursor step for the externalization of VP1ur.  
For MVM full capsids conversion of VP2 to VP3 by proteases allows 
immunoprecipitation with anti-VP1ur antibodies at lower temperatures than uncleaved 
capsids, starting at 45 degrees (55).  Particles that are not treated with proteases must 
be heated to approximately 60°C before VP1ur can be detected, and heating CPV to 
60°C also releases VP1 (55, 195).  This indicates that the conversion of VP2 to VP3 
promotes externalization of VP1ur.  Other laboratories however, have reported by 
immunofluorescence, that empty particles (where VP2 cannot be converted to VP3) 
can still release VP1ur, and it is possible that other factors encountered during 
infection also help to release VP1ur (99).  The endosomal proteases such as cathepsins 
are most likely to be responsible for the VP2 to VP3 cleavage, and those are activated 
by low pH and inhibition of this pH abrogates viral infectivity (74).  Yeast two-hybrid 
study of binding partners for the capsid protein of another parvovirus, adeno-
associated virus (AAV), identified cathepsins B and L as important in AAV 2 and 8 
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infection, and these proteases will cleave capsids without disassembling them (6).  In 
vitro treatment of CPV with cathepsins converts VP2 to VP3, but showed no further 
cleavage of capsid protein (197).  There is only one disulfide bond in the structure of 
CPV, and it is unlikely that reducing conditions would have a large impact on the 
structure of CPV. 
CPV binding to TfR may also cause conformational changes in the capsid.  
Cryo-EM and 3D asymmetric image reconstruction along with biochemical studies 
showed that only a small number of purified feline TfR ectodomain molecules bound 
to each capsid, despite an excess of the receptor in those samples (63).  Modeling the 
structure of TfR onto the CPV capsid demonstrates that between 20 and 24 receptors 
should be able to bind to the virus without steric clashes (in this case 2 receptors at 
each 3-fold or 5-fold axis, respectively).  Purification of CPV:feline TfR complexes 
showed only 7 or fewer receptors bound per virus, as determined by quantative slot 
blots.  Also, soluble TfR competed with cellular TfR for binding to CPV at 
concentrations as low as 3 sTfR per capsid.  This suggests that binding of TfR may 
induce a conformational change in the virus that precludes binding of other receptor 
molecules, or that there are a limited number of available binding sites on each capsid.  
The resolution of the cryo-EM reconstruction, was not great enough to detect any 
conformational changes.  Another possibility is that there is inherent structural 
asymmetry in the virus that would allow receptor binding to only a limited number of 
sites on the surface of the virus.  
 
1.10d Penetration of endosomes by CPV. 
CPV is believed to escape from endosomes by use of its PLA2 domain within 
VP1ur.  The highest activity of these PLA2 at pH 6-7 along with the need for 
millimolar amounts of calcium, suggests that if this enzyme is necessary for escape 
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from endosomes, then it would most likely occur in a relatively early endosome, or in 
a moderately low pH endosome (such as a recycling endosome).   
How exactly any membrane modification by the CPV PLA2 leads to particle 
penetration is still not well understood.  Cellular PLA2 promotes exocytosis by 
causing fusion of exosomes to the plasma membrane, and can fuse in vitro (19, 111, 
114).  Annexins are proteins that bind to phospholipids and promote fusion, and their 
activity requires arachidonic acid.  Therefore, liberation of arachidonic acid by PLA2 
is believed to be responsible for this membrane fusion (108).  Since parvovirus PLA2s 
will liberate arachidonic acid from mammalian cells, it is possible that modification of 
membranes and fusion of endosomes by the PLA2 is involved in the infectious process 
(15). 
The PLA2 domain, along with the rest of VP1ur is believed to be externalized 
from the 5-fold pore, in a partially or completely unfolded form.  Unlike most other 
secretory PLA2s, the PLA2 of CPV lacks disulfide bonds, and this may help in the 
externalization of this domain through the narrow pore (203).  Alternatively the pore 
may expand to allow passage of the folded domain, as apparently occurs when the 
VP2-N terminus is externalized.  As VP1ur is externalized in endosomes, it is believed 
that the PLA2 is active at this point or a later step (99).  The PLA2 domain however 
does not appear to cause complete lysis of endosomes, as determined by co-incubation 
of CPV with FITC labeled dextrans (171).  After release from the endosome, the 
virion may engage components of the microtubule trafficking system including 
dynein, and move to the perinuclear region before entry to the nucleus. 
 
1.10e Cytoplasmic trafficking and entry of CPV into the nucleus. 
The CPV genome must enter the nucleus for productive infection, however the 
steps leading up to this event are still not well characterized.  CPV is believed to be 
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directly exposed to the cytoplasm after escape from endosomes, as microinjection of 
anti-capsid antibodies into the cytosol will block infection by virus added to the cells 
(196).  Capsids display NLS motifs in the VP1ur, and the virus is small enough to 
enter through the nuclear pore complex, with the help of the karyopherin transport 
system (43, 64).  An alternate mechanism of nuclear entry has been proposed, where 
parvoviruses capsids would directly perforate the nuclear membrane by an unknown 
mechanism, thereby bypassing the nuclear pore complex (38, 39). 
 
1.10f DNA release. 
The 3’ end of the DNA is not initially accessible in intact virions, yet it must 
become exposed during infection to engage the host DNA polymerase.  To date, no 
structural or biochemical studies have determined the location of the 3’ end of the 
DNA or how accessibility to the 3’ end is accomplished.  It appears that the DNA can 
become exposed from the particle without disassembly as in vitro studies of MVM and 
B19 show that the capsids remain intact while the DNA can be accessed by DNA 
polymerases at temperatures above 60°C for MVM, or 50°C for B19 (45, 146).   By a 
microscopy based approach using biotinylated nucleotide probes, MVM virions were 
shown to expose the 3’ end of the viral DNA in endosomes (99). 
 
1.11 Viral entry and uncoating of other nonenveloped viruses. 
The steps leading to membrane penetration by the viral particle can be 
conceptually divided into four phases (reviewed in (184)).  The particle must first 
enter the cell and traffic to the site of membrane penetration.  Next the virus must 
undergo a conformational change that activates or exposes a membrane-modification 
or disruption activity.  This newly exposed factor then disrupts the membrane, and the 
particle crosses the membrane to enter the cytoplasm.  
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While some enveloped viruses can fuse directly at the plasma membrane, most 
nonenveloped viruses require endocytosis (104).  This is most likely because 
endocytosis allows viruses to sense the presence of the cell interior, to bypass the 
dense cortical actin network that lies directly under the plasma membrane, and to 
traffic within the cell (25, 103).  Various viruses are taken into cells by most known 
endocytic pathways including macropinocytosis (adenovirus), clathrin-independent 
endocytosis (arenaviruses and influenza), clathrin-mediated endocytosis (parvovirus, 
adenovirus, influenza), and caveolar and related entry pathways (SV40, coxsakie B, 
echo virus 1) (reviewed (104))(85-87, 100, 109, 132, 144, 145, 159).  These pathways 
are often not exclusive for a given virus, and many viruses can use multiple pathways 
(48, 152).  Poliovirus is endocytosed by a clathrin- and caveolin-independent pathway, 
and has been demonstrated to release its genome within the 100-200 nm of the plasma 
membrane, in response to unidentified host factors (17, 50, 73).  Since poliovirus 
replicates in the cytoplasm, the virus does not need access to the nucleus, and 
therefore the cortical actin and the endosomal membrane likely offer the main barriers 
to viral entry.  Other viruses must undergo trafficking to reach the correct site of 
uncoating.  For example, SV40, a polyomavirus, binds to the glycolipid GM1 (and 
possibly MHC class I) on the surface of cells (8, 18, 185).   After binding, SV40 
diffuses laterally on the surface of cells until it localizes to caveolin-enriched lipid 
rafts (131).  Once in these rafts, signaling occurs that results in pinching off of 
cavolae, and trafficking to tubular-vesicular endosomes called caveosomes within the 
cell (130, 131, 173).  From the caveosomes, SV40 is pinched off in vesicles that lack 
caveolin-1, and those traffic to and fuse with the smooth ER along microtubules, 
where SV40 translocates across the ER membrane.  Entry of adenoviruses appears to 
use both clathrin mediated endocytosis and macropinocytosis (reviewed in (104)).  
Adenovirus binds to the coxsakie virus adenovirus receptor (CAR) with its fiber 
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protein, and also to integrins using an RGD motif within the penton (11, 143, 198).  
After endocytosis, release of the virus is triggered to allow escape into the cytosol 
(199). 
After trafficking to the correct location within the cell, the nonenveloped virus 
capsid must undergo conformational changes that result in the release of membrane 
lytic or of membrane modifying factors, and these can involve various mechanisms 
including receptor binding, redox chemistry, low pH, and protease digestion.  For 
poliovirus, binding to PVR either in vitro or on the surface of cells catalyzes 
conformational changes in the capsid that results in swelling of the particle (reviewed 
in (66))(49, 57, 186).  The ultimate result of these conformational changes is the 
exposure of the N-terminus of VP4 to the outside of the particle, which was previously 
sequestered within the particle (58).  This N-terminus is myristoylated, and inserts into 
membranes upon exposure (35, 106, 189).  SV40 undergoes conformational changes 
when it reaches the smooth ER.  In the ER, SV40 and the closely related Py virus 
utilizes protein folding and disulfide isomerization machinery to uncoat (98, 155).  
Particle stability is accomplished through changes in disulfide bonds between capsid 
subunits controlled by the isomerization protein ERp57 in the lumen of the ER, which 
acts to break and reform the disulfide linkages and similar changes are seen in vitro by 
treatment with DTT and EGTA (14-16, 40, 75).  This isomerization activity, coupled 
with calcium removal from the capsids results in removal of approximately 12 of 72 
pentamers from the capsid (155).  Isomerization of disulfide bonds and calcium 
removal are also important for the exposure of VP2 and VP3, which are normally 
located on the interior of the capsid.  The N-terminus of VP2 is myristoylated and it is 
thought to insert into membranes to create pores (84, 170).  Adenovirus enters cells 
and comes in contact with low pH endosomes (reviewed in (91)).  This low pH 
activates a viral protease that cleaves some capsid proteins, destabilizing the capsid 
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and liberating a number of capsid proteins (62, 199). Protein VI is normally 
sequestered within capsids, but upon exposure will lyse endosomes through the use of 
its amphipathic N-terminus.  This allows escape of adenovirus to the cytoplasm where 
it will traffic to the nucleus to replicate.  Finally, reoviruses undergo conformational 
changes after protease processing outside the cell or in late endosomes.  After 
endocytosis, capthepsins B and L cleave the outer capsid protein σ3 to generate 
intermediate subviral particles (ISVPs) (9, 51).  Those intermediate particles are 
further processed to release the N terminus of the µ1 protein (called µ1N), which is 
normally buried within the capsid (30).  The release of µ1N is accomplished by 
dramatic conformational changes to the capsid (204).  The released µ1N reacts in 
trans with other intermediate particles to release more µ1N in a positive feedback loop 
(5).  The released µ1N is myristoylated at its N-terminus and is responsible for 
inserting into membranes and causing pore formation (76). 
Penetration and crossing membranes by enveloped viruses is a more 
straightforward process than for nonenveloped viruses, since fusion of the viral 
envelope to the host membrane will result in the release of the nucleocapsid across the 
barrier (184).  For nonenveloped particles, the particles must lyse membranous 
organelles, hijack the host protein translocation machinery, or modify membranes in a 
way that allows trafficking of the particle or genome across the membrane.  One 
suggested mechanism that is often observed is through the formation of pores by viral 
proteins.  The VP4 N-terminus of poliovirus for example, inserts into membranes after 
PVR-induced exposure (189).  Recent cryo-EM or cryo tomography and image 
reconstructions have visualized poliovirus bound to PVR-decorated liposomes (13, 
20).  These models show the binding of five PVR molecules around the 5-fold axis of 
symmetry and disruption of membrane below this axis, possibly as a result of insertion 
of the VP4 N-terminus into the membrane.  The insertion of the N-terminus of VP4 is 
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thought to destabilize the membranes and allow release of the RNA into the 
cytoplasm.  The µ1N of reovirus has also been shown to induce pore formation in both 
lipsomes and in resealed red blood cell ghosts (4).  However, the average pore size 
formed is on the order of 4-9 nm, which is around one tenth the size of the reovirus 
particle.  Since the entire particle is believed to be released into the cytosol, it is 
thought that osmotic pressure may lyse the endosome, or the pore may be expanded by 
other unidentified factors.  SV40 and the closely related mouse polyoma virus (Py) 
have been shown to hijack host transport machinery to gain access to the cytosol.  
These viruses appear to use the ER-associated degradation (ERAD) pathway, which 
normally functions to retrotranslocate misfolded proteins back to the cytosol for 
degradation (92, 155).  However, interaction of SV40 and Py with ERp57 also causes 
exposure of the myristoylated N-terminus of VP2, which inserts into membranes 
(136), and at this point it is not clear whether VP2 or the ERAD pathway is 
responsible for trafficking of particles across the ER membrane.   
 
1.12 Host range of CPV and FPV. 
CPV is a new virus of domestic dogs and related canines, emerging in the late 
1960s from feline FPV or a related virus of other members of the Carnivora.  FPV and 
CPV are >99% related in amino acid sequence identity and show conserved 
differences of 9 amino acids in the VP2 sequences (107, 126).  Binding to TfR is a 
primary determinant of host range, although there is some complexity in the 
connection between receptor binding and host specificity.  Both CPV and FPV bind to 
the feline TfR, but only CPV capsids are able to bind to the canine TfR (70).  
However, early strains of CPV (termed CPV type-2, isolated in 1978) are able to 
infect feline cells but do productively infect cats (124, 183).  FPV isolates can 
replicate in cells in the thymus of dogs in experimental infection, indicating that there 
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are additional constraints to host range besides simple TfR binding (181, 183).  A 
mutant of FPV that contains residues 93 and 323 of CPV is able to bind to canine TfR, 
and residues 80, 564 and 568 were also shown to affect the success of CPV in dogs 
(68, 180, 182).  CPV-2a, which emerged in 1979 as a variant of the ancestral CPV-2 
regained the ability to infect cats, and capsid protein changes were involved in this 
gain of function (22, 44, 105, 112, 129, 153, 181).  Comparison of the atomic 
resolution structures of FPV and CPV-2 capsids showed only small differences 
between the two viruses (61).  The capsids of FPV coordinate an additional calcium 
ion and additional hydrogen bonds in the capsid protein controlled by the host range 
determining sequences (residue 93), and may therefore have less flexibility in several 
surface loops compared to CPV ((128)).  It is not clear how these changes affect host 
range, but they may influence the interaction of the capsid with feline and canine TfRs 
and with other host factors.  The canine TfR has an extra glycosylation site, and 
removal of this modification allows that receptor to bind to FPV capsids (119).  It is 
likely that part of the evolution of FPV to CPV was a gain in the ability to more 
favorably interact with this extra glycan. 
 
1.13 Neutralization of viruses. 
A detailed understanding of the host immune response to viral infection is 
critical for development of new anti-viral therapeutics and vaccines.  Antibodies (Abs) 
play major roles in protection of the host from infection and clearance of viremia 
during systemic infections (23).  The full spectrum of Ab responses against viruses is 
large and complex.  Since this complexity makes a detailed understanding of Ab 
protection difficult, in vitro studies using monoclonal antibodies (MAb) offer a 
tractable way to study a subset of the Ab response (137).  As used here, the term 
neutralization refers to the ability of an Ab to block viral infection in vitro by binding 
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directly to the virus (79).  Other mechanisms of antibody-mediated viral inactivation 
can include cellular effector functions such as complement fixation, antibody 
dependant cellular cytotoxicity, opsinization, or Fc mediated phagocytosis.  It is likely 
that mechanisms of neutralization seen in in vitro studies would also function similarly 
in an infected animal as part of the defense against or recovery from infection. 
Extensive research has been done on neutralization of nonenveloped viruses; 
however many of the mechanisms of neutralization are still not well understood.  In 
the early studies problems included the use of polyclonal and intact (multivalent) Abs 
which made it difficult to identify the viral epitopes and often confused Ab binding 
constants (162).  Examining the effects of fragment, antigen binding (Fab) of MAbs 
allows the combination of structural and biochemical data into a mechanistic 
understanding of capsid-antibody interactions.  X-ray diffraction on icosahedral 
capsid-Fab complexes yields the greatest amount of structural information, however 
the growth of crystals of such complexes has been difficult, with human rhinovirus 14 
and an Fab fragment being the only successfully solved complex (165).  Cryo-EM and 
3D image reconstructions can readily image capsid-Fab complexes, but sofar provide 
lower resolution models than crystallographic data.  To increase the effective 
resolution of cryo-EM models, pseudo-atomic resolution structures may be used, 
where the atomic resolution structures of each component (solved separately by X-ray 
diffraction) are fitted into the electron density maps of reconstructed cryo-EM models 
(149).  This allows the interpretation of Ab footprints on the surface of the virus, and 
in some cases has been successful in identifying conformational changes after Ab 
binding (93, 162).  Other attempts at understanding the virus-antibody interaction have 
relied on crystallizing Fabs with peptides that resemble the antigenic sites on the virus 
(191), although there may then be concerns that the peptides do not form the same 
conformation as the assembled capsid protein. 
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The mechanisms by which Abs neutralize viruses are becoming increasingly 
clear.  In some models the Fabs of IgGs appear to neutralize viruses by blocking 
receptor binding, by preventing conformational changes necessary for infection before 
or after the virion binds cells, by causing conformational changes to the virus, or by 
preventing correct endocytosis of the virus by blocking virus-induced cell signaling or 
co-receptor binding (32, 52, 53, 60, 82, 97, 115, 116, 190).  Intact IgGs also neutralize 
virus by aggregation of capsids to lower the effective number of infectious units, and 
in some cases the IgG can bivalently bind to a single particle to increase the apparent 
affinity or prevent viral uncoating (23, 80).  While all of these mechanisms are 
possible, a survey of recent structural and biochemical data suggests that many Abs 
act to prevent binding of virions to host cells through simple steric hindrance of the 
virus-receptor interaction (162). 
Human rhinovirus (HRV) is a well-studied example of capsid-Fab interactions.  
The structure of a neutralizing MAb bound to HRV14 has been determine by cryo-EM 
and image reconstructions and also by X-ray diffraction on intact capsid-Fab 
complexes.  Both of these structures showed that large conformational changes did not 
occur in the capsid after Fab binding (163, 164, 166), but instead structural changes 
occur to the CDR3 of the Fab, which allowed it to bind better to the capsid (163).  
This Fab also binds in the same area of the capsid as the cellular receptor, and 
competes for receptor binding (41).  In this case the intact IgG binds bivalently to the 
virus across a twofold axis of symmetry, but it is not clear whether this is necessary 
for neutralization, or acts by increasing the Ab affinity (166).  Interestingly, Fab 
binding acts to stabilize the virus and prevents some movements that occur in the viral 
proteins (breathing) in way similar to anti-viral compounds (138).  This study 
indicates part of the complexity of studying neutralization: even though this Fab may 
neutralize primarily by preventing receptor binding, other mechanisms such as 
40 
 
 
 
stabilization of capsids may also aid in neutralization.  Neutralization by steric 
hindrances occurs for many other nonenvelped viruses including reoviruses (113), 
adenoviruses (168), possibly papillomaviruses (12), foot and mouth disease virus, 
caliciviruses (177), and parvoviruses (200). 
 
1.14. Immune responses during CPV infection. 
Antibodies are believed to play a critical role in preventing CPV infection.  
Puppies that acquire maternal immunity are protected from infection, and they become 
susceptible only when the antibodies wane to low titers.  In many cases there are still 
detectable levels of antibody present when the pups are infected.  In laboratory 
experiments, passive transfer of sera from immunized animals to naïve puppies will 
protect the recipients from infection (134).  Also maternal antibodies will interfere 
with administration of the live-attenuated CPV vaccine, indicating that antibodies also 
inhibit replication of the vaccine virus (27).  It is not known what role T-cells play in 
clearance of viral infection, although several T-cell epitopes near the C-terminus and 
the N-terminus of VP1 have been described (141, 142)  
The CPV capsid itself is highly immunogenic, and vaccination of dogs with 
formalin inactivated CPV induces serum antibody titers that persist up to either 20 
week (with no boost immunization) or 50 weeks (with booster)  (135).  Vaccination 
with a live attenuated strain of CPV protected dogs for at least 24 months and induced 
persistently high antibody titers (27).  In addition, baculovirus-produced VP2-only 
viral like particles (VLPs) are able to fully protect animals with a dose of as little as 
one microgram.  Most of the B-cell epitopes identified are within the VP2 region of 
the capsid (88, 96, 142, 169).  This is in contrast to B19, where major neutralizing 
epitopes are present in VP1ur, and this difference may be the result of difference in 
surface accessibility of this region (154).  Several studies have identified linear B-cell 
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epitopes of CPV using synthetic peptides or protein fragments expressed in bacteria. 
These studies demonstrated that the amino terminus of VP2 (residues 1-23) is a 
functional B-cell epitope, as well as residues near the C-terminus (residues 549 and 
573, VP2 numbering), and other residues that are believed to be on or near the surface 
of the virus (residues 91, 172, 283, 297, and 498, VP2 numbering) (96).  A variety of 
antibody epitopes on CPV were identified by escape mutant analysis (169), which 
clustered into two sites, termed site A and site B.  While these were mouse 
monoclonal antibodies, it is likely that the rodent response was similar to the natural 
canine antibody response to CPV infection.  Residues which affected binding of MAbs 
to site A are 93, 222, 224, and 426, while for site B, residues 299, 300, and 302 were 
important.  Those residues were identified by escape mutant analysis, and it is possible 
that mutation of these residues would have an allosteric effect on the capsid, and the 
actual antibody epitopes are located elsewhere on the capsid.  However, the clustering 
of the changes into two small regions suggest that those are within the footprints of the 
antibodies.  In all the studies to date the antibodies studied were immunoglobulin G 
proteins (IgG), which represent the high affinity antibodies that develop against the 
virus.  It is not known whether the earlier and lower affinity IgM antibodies would 
bind to different areas of the capsid.  Analysis of antibody binding to CPV is 
complicated by the fact that many mutations affect more than one function - for 
example the Lys to Asn change of VP2 residue 93 changed both the antigenic 
structure of the capsid and the specificity of binding to TfR that controls canine host 
range.  The sites A and B may be the structures on the capsid that can establish 
interactions with other proteins, and therefore bind both the TfR and antibodies.  It is 
more likely that there is a complex interplay between receptor and antibody binding, 
as the footprints of TfR and Fabs overlap (Figure 1.5).  A practical implication of this  
 
 
Figure 1.5. 
The interplay between receptor and antibody binding.  Residues important for receptor 
binding are shaded in green.  Residues important for binding site A antibodies are 
shaded red and site B are shaded blue.  Shared residues between receptor and site A 
are shaded in yellow, and residues shared between receptor and site B are shaded in 
teal. 
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interplay is that it is extremely difficult to understand whether naturally arising 
mutation in the virus are a result of antibody selection or receptor binding, or both.  
 
1.15 Thesis overview. 
This thesis will explore the biochemical effects of conditions that mimic the 
entry of CPV into cells.  It will also examine the relationship between receptor and 
antibody binding, and the effect of that binding on the structure of the virus. 
Chapter 2 will discuss the mechanisms of neutralization of CPV by intact IgGs 
or Fabs of monoclonal antibodies.  The competition between Fabs and TfR will also 
be examined. 
Chapter 3 will describe the visualization of antibody footprints on the virus by 
Cryo-EM and image reconstruction techniques.  I will describe these footprints and 
their relationship to viral epitopes. 
Chapter 4 will describe the effects of low pH, calcium removal, increased 
temperature, and ligand binding on the structure of the capsid.  
Chapter 5 will summarize the work presented here and offer insights into 
potential future research projects. 
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CHAPTER TWO 
Different mechanisms of antibody-mediated neutralization of parvoviruses 
revealed using the Fab fragments of monoclonal antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Christian D.S. Nelson, Laura S. Palermo, Susan L. Hafenstein, and Colin R. 
Parrish. 2007. Different mechanisms of antibody-mediated neutralization of 
parvoviruses revealed using the Fab fragments of monoclonal antibodies. Virology. 
(361) 283-293. 
 
[Laura Palermo was a graduate student in Colin Parrish’s laboratory who provided 
transferrin receptor for these experiments.  Susan Hafenstein is a post-doctoral 
research associate in Michael Rossman’s Laboratory who designed figure 2.7] 
71 
 
 
 
2.1 Abstract. 
Antibody binding and neutralization are major host defenses against viruses, 
yet the mechanisms are often not well understood.  Eight monoclonal antibodies and 
their Fab fragments were tested for neutralization of canine parvovirus and feline 
panleukopenia virus.  All IgGs neutralized >90 percent of virus infectivity.  Two Fabs 
neutralized when present at 5 nM, while the others gave little or no neutralization even 
at 20-100 nM.  The antibodies bind two antigenic sites on the capsids which overlap 
the binding site of the host transferrin receptor (TfR).  There was no correlation 
between Fab binding affinity and neutralization, indicating that the specific antibody 
epitope may be more important in determining neutralization.  All Fabs reduced capsid 
binding of virus to purified feline TfR in vitro, but the highly neutralizing Fabs were 
more efficient competitors. All partially prevented binding and uptake of capsids by 
feline TfR on cells. The virus appears adapted to allow some infectivity in the 
presence of at least low levels of antibodies. 
 
2.2 Introduction. 
Protection and recovery from viral infection in animals are complex processes 
that involve many components of the innate and adaptive immune systems, and 
antibodies are a critical adaptive immune response against most viruses of vertebrates 
(6).  Antibody neutralization is defined as the “abrogation of virus infectivity in vitro 
by the binding of antibodies to the virion” (31), and that binding may affect the virus 
at one or more stages in the viral infection cycle.  In different models antibodies have 
been shown to crosslink and aggregate virions (10), prevent viral attachment to cells 
(32), block receptor binding by steric hindrance or by preventing viral conformational 
changes required for infection (10, 40), inactivate the virus before cell binding occurs 
(reviewed by (17))(16, 23, 50), or prevent infection after uptake into cells (49, 
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81)(reviewed in (31)).  Additional antibody-mediated mechanisms occur in vivo, 
where they can cause  Fc-mediated phagocytosis, complement binding and activation, 
opsonization, and antibody-dependant cellular cytotoxicity of infected cells (6). 
Viruses and their hosts have been co-evolving for long periods, and the 
antigenic sites of viral structural proteins will be those that allow highest viral fitness 
in the face of antibody selection.  Different viruses show various levels of antibody 
binding and differ in their ability to accommodate antigenic variation.  Some viruses 
(such as rhinovirus, influenza, and HIV) either come in many serotypes or are able to 
tolerate amino acid variation to escape from or avoid the antibody responses of their 
hosts (21, 26, 37, 73). Other viruses (such as measles virus or polioviruses) are found 
as only 1 or a small number of antigenic types even after long periods of selection and 
are apparently unable to vary antigenically to escape preexisting antibodies (65, 66, 
69, 70).  These differences in antigenic structure and variation likely result from 
differences in the replication of the viruses, their modes of transmission, and the 
abilities of their structural proteins to accommodate antigenic change while still 
maintaining other viral properties (2, 83). 
Although often considered a factor in antibody neutralization, the relationships 
between the antibody and receptor binding sites have only been examined directly in a 
few cases.  Some receptor binding sites are conserved and buried in clefts or other 
protected structures that are at least partially inaccessible to antibodies (68), while 
other receptor binding sites are on prominent structures and show significant overlap 
with the antibody binding sites (15, 38). 
Parvoviruses are small and have simple capsids made of essentially a single 
protein structure, and they do not appear to encode genes that can specifically 
manipulate the immune responses of their hosts. Despite this simplicity, they cause a 
variety of different types of disease, with acute infections in many cases.  However, 
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several of the parvoviruses form persistent infections, indicating that they are able to 
persist in the face of host immunity.  Canine parvovirus (CPV) and feline 
panleukopenia virus (FPV) have 25nm nonenveloped T=1 icosahedral capsids that are 
assembled from 60 copies of a mixture of viral proteins.  The infectious capsids 
contain ~55 copies of VP2, and ~5 copies of the VP1 protein which in CPV and FPV 
contains both the VP2 sequence and an 143 additional N-terminal residues (80, 91).  
Full (DNA-containing) capsids have about 20 residues of some the VP2 N termini 
exposed on the outside of the capsid where they may be cleaved by host proteases to 
form VP3, and those N-termini are likely exposed through a pore at the five-fold axis 
of symmetry (86, 91).  Elaborate loops forming most of the capsid surface  make up 
most of the functional sites of the capsid, including those involved in receptor and 
antibody binding (1, 24, 27, 76, 80, 88). 
The cell receptor for CPV and FPV is the transferrin receptor (TfR), and 
appropriate TfR binding leads to cell infection (29, 54).  The TfR assembles as a stable 
homo-dimer, and each monomer is made up of 3 domains: a protease-like domain, an 
apical domain, and a helical domain.  Transferrin and hereditary hemachromatosis 
protein bind to the membrane proximal portions of the protease-like and helical 
domains (12, 22, 36, 87) whereas CPV and FPV bind to the apical domain (53).  
Canine TfR binding to the CPV capsid is affected by residues in three positions on the 
threefold spike that are ~20-30Å apart, suggesting that the receptor binds to a broad 
surface of the capsid (24, 27). 
There is variation among the CPV- and FPV-like viruses that is associated with 
differences in their host ranges.  The original CPV strain (termed CPV type-2 (CPV-
2)) emerged in 1978 due to a small number of mutations of an FPV-like virus which 
altered both receptor and antibody binding sites on the capsids.  A further 4 or 5 
mutations in the capsid protein gene of CPV-2 resulted in the emergence of a variant 
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virus (CPV type-2a (CPV-2a)) in 1979 which replaced CPV-2 worldwide within two 
years (56, 60, 61).  CPV-2a differs from CPV-2 in affinity for the feline TfR and also 
in antigenic structure as defined by monoclonal antibody (MAb) binding (53, 56, 61).  
Those strains of virus also differ in canine and feline host ranges, as FPV infects cats 
but not dogs, CPV-2 strains infect dogs but not cats, while CPV-2a and later viruses 
infect both cats and dogs (45, 78, 79).  Since 1980, variations of single residues in the 
capsid have become widely selected, including VP2 residue Asn426 to Asp (after 
1984, designated the virus being designated CPV-2b (56)), VP2 residue Ser297 to Ala 
around 1990, and residue Asp426 to Glu after 2000 (4). 
The antigenic structure of CPV and FPV has been examined by MAb binding,  
analysis of peptide binding by polyclonal sera, cryoelectron microscopic (cryoEM) 
analysis of capsid:Fab complexes, and analysis of natural and selected antigenic 
variants (7, 25, 34, 35, 57, 63, 76, 78, 88).  Cross-competition studies of MAb binding 
and analysis of sequences that determine antigenic variations show that the epitopes 
can be divided among two major antigenic sites designated A and B (57, 76).  
Although site A is near the top of the threefold spike and site B is on the side 
(shoulder) of that structure, both epitopes are composed of multiple loops so that the 
binding sites are conformational in nature (76, 80, 88, 91). Although FPV or mink 
enteritis virus (MEV) isolates collected over many years show little antigenic variation 
(57, 59), both A and B site changes have been detected in CPV isolates from dogs and 
cats (42, 46, 47, 56, 61). 
Panels of MAbs have been generated against FPV, CPV-2, and CPV-2b 
capsids, and all of those antibodies neutralized virus infectivity when tested as IgGs 
(76).  When the antibody binding (variable) domains of two MAbs were expressed as 
single chain variable domains (scFvs), they neutralized infectivity, although at levels 
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lower than the corresponding IgGs, and that neutralization was in part due to cross-
linking and aggregation of the capsids by dimeric forms of the scFv (92). 
Here we examine the processes of antibody neutralization of canine and feline 
parvoviruses.  We tested 8 different MAbs recognizing either site A or B for their 
abilities to neutralize the viruses as IgGs and Fabs.  While all IgGs neutralized the 
viruses, only two of the Fabs recognizing site B efficiently neutralized viral 
infectivity, one was weakly neutralizing, and the other Fabs showed little or no 
neutralization.  All Fabs at least partially inhibited the binding of capsids to the 
purified feline TfR, but the highly neutralizing antibodies showed the greatest 
inhibitory effect.  There were only modest differences in the affinity of binding of the 
Fabs, but the highly neutralizing antibodies were not uniformly of higher affinity.  
Efficient neutralization by Fab binding likely results from either Fab-induced 
differences in the capsid-TfR interaction, or to effects on later stages of infection. 
 
2.4 Materials and Methods. 
Cells and viruses.  Crandell Reese Feline Kidney Cells (CRFK) were grown 
in a 1:1 mixture of McCoy’s 5A and Lebovitz L-15 media with 5% fetal calf serum 
(FCS).  TRVb hamster cells which lack TfR were grown in Hams F-12 medium with 
5% FCS, and were transfected with plasmids expressing the feline TfR (TRVb-fTfR) 
and selected with 400 μg/ml G418 (28) .  FPV, CPV-2, and CPV-2b virus stocks were 
prepared from infectious clones transfected into CRFK cells as previously described 
(55), and stored at -80oC in aliquots. 
Purified Transferrin Receptor.  Soluble TfR ectodomain was produced by 
baculovirus expression in insect cells as previously described (28, 52).  The dimeric 
protein was isolated by size exclusion chromatography through a S300 column. 
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Capsid concentration measurements.  Capsid concentrations in virus 
samples were determined using a capture ELISA.  Purified rat anti-CPV (MAb F) 
bound to an ELISA plate was used to capture virus from the test samples or controls 
containing known amounts of purified virus.  After 1 h the plate was washed with 
phosphate buffered saline with Tween 20 (PBST). The plates were incubated with a 
mouse anti-CPV (Mab 8), then with a specific goat anti-mouse HRP-conjugated 
antibody, and 2,2’-Azino-bis(3-ethyl bensthaxoline-6-sulfonic acid) (ABTS) substrate 
for 30 min. 
Anti-CPV and FPV antibodies.  Eight different hybridomas were chosen 
which produced IgG antibodies against CPV or FPV capsids (Table 2.1)(57, 58).  
Hybridomas were grown in 500 ml volumes in gas permeable bags (Nexell, Irving, 
CA) containing Dulbecco’s minimal essential medium with 5% FCS, then the IgGs 
were purified using Protein G (GE Healthcare, Piscataway, NJ).  Fabs were generated 
using papain digestion; the Fc portions removed with protein A (GE Healthcare), and 
the monomeric Fabs were purified by chromatography in a Sephadex G100 column in 
PBS.  Protein concentrations were determined by A280 and by bicinchoninic acid 
(BCA) assay. 
Virus neutralization assays.  CRFK cells were seeded into 96 well trays at 
1.28 x 104 cells per cm2 and incubated overnight.  104 TCID50 of virus and various 
amounts of IgG or Fab were mixed with DMEM to give a final volume of 0.4 ml.  
After 1 h at 37°C, each virus was diluted in 10-fold series, and 0.05ml added to 
replicate wells.  After 1 h at 37oC, 0.1 ml of growth medium was added and cells were 
incubated for 48 hrs.  After fixation the infected cells were detected by antibody 
staining as described (92), and the TCID50 titers calculated. 
Affinity of Fabs for CPV.  Affinities of Fabs were determined by direct calibration 
ELISA (20).  Three separate experiments were performed to obtain variables used in 
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determination of affinity.  Unless otherwise noted100 ng of capsids and 10 ng of Fabs 
per well were used, Fabs were diluted in blocking buffer (PBST with 0.5% w/v 
ovalbumin), and plates washed six times with PBST between incubations.  Fabs were 
detected with either an anti-mouse or anti-rat HRP-conjugated secondary antibody.  
Capsids were immobilized to Maxisorp plates (Nunc, Rochester, NY) in carbonate-
bicarbonate buffer (pH 9.6) overnight at 4oC.  These plates were washed and then 
blocked with blocking buffer for 2.5 h before use in each experiment. 
To determine the rate of Fab-CPV complex formation, Kc, Fabs and capsids were 
incubated for various times before the unbound Fabs were removed, wells washed and 
100 µl of PBST was left in each well until the last time point was completed, when the 
bound Fabs detected.  Non-linear regression analysis estimated the maximum 
absorbance for each Fab after infinite binding time.  The absorbance correlates with 
the concentration of Fab-CPV complexes by an unknown calibration factor, c.  The 
calibration factor was determined by incubating Fabs with immobilized capsids for 
varying times, and then serially transferred to more immobilized capsids.  The amount 
of each Fab transferred or retained is determined by the transfer factor, F.  After 4 
transfers, the plates were washed, bound Fabs were detected, and F and c determined. 
The amount of CPV immobilized to the plate was determined by a saturation analysis.  
Fab concentrations ranging from 166 to 0.04 nM were allowed to interact with capsids 
for 3.5 hr, plates were washed and Fabs detected.  Non linear regression analysis was 
used to determine the maximum binding that would occur with an infinite 
concentration of Fabs, and this was used to determine the immobilized CPV 
concentration by the calibration factor c.  Affinities were determined by the equation 
Ka = (1 – F)/(F * CPVimmbolized). 
 
 
TABLE 2.1. 
Monoclonal antibodies used in these studies, along with the known specificity for 
particular viruses, and the escape mutants that affect their binding. 
Antibody 
ID 
Source 
Epitope 
recognized
Specificity 
Escape mutations (residue in 
VP2 sequence) 
14 Mouse Site A CPV only 
93 N-K, 224 G-R, 224 G-E, 
222 H-Y 
15 Mouse Site B CPV, FPV 299 G-E (300 A-D partial) 
16 Mouse Site B CPV, FPV 299 G-E, 300 A-D, 302 N-D 
6 Mouse Site A CPV, FPV 222 H-Y, 224 G-R, 224 G-E 
8 Mouse Site B CPV, FPV 300 A-D, 302 N-D 
B Rat Site A CPV, FPV 222 H-Y, 224 G-R, 224 G-E 
F Rat Site B CPV, FPV No escape mutant recovered 
E Rat Site B CPV, FPV 300 A-D 
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Competition with capsid binding to the feline TfR.  The effects of the Fab 
on capsid binding to the feline TR were tested using in vitro binding assays.  Purified 
feline TfR ectodomain was coated onto Maxisorp black plates (Nunc) in pH 9.6 
carbonate buffer at 4oC overnight.  After washing the plates were incubated 
withblocking buffer for 1 h.  The Fab fragments were incubated at various 
concentrations with the CPV-2 empty capsids labeled with Cy2, and then after 1 h the 
mixtures were added to the wells containing the feline TfR.  Control Fabs were 
prepared from antibodies directed against the capsids of AAV-1 or AAV-5, which did 
not react with the CPV capsids.  After 1 h incubation, the plates were washed and the 
capsid fluorescence bound determined in a fluorescence reader (Tecan Sapphire, 
Durham, NC). 
Cell binding and uptake.  Fluorescence microscopy was used to examine the 
ability of Fab bound capsids to bind and enter cells.  Cy-2 labeled CPV-2 or FPV 
capsids were incubated with Fabs at ratios between 1:100 to 1:20 for 1 h at 37°C.  
CRFK cells, or TRVb- cells expressing the feline TfR were washed 3 times with 
DMEM containing 0.1% BSA, then incubated with Fab-CPV mixtures for 1 h at 37°C.  
Cells were washed with PBS, fixed in 2% paraformaldehyde (PFA) for 10 min, then 
washed and visualized under the fluorescent microscope.  Images were collected at the 
same exposure in both phase contrast and fluorescence, and analyzed for virus 
fluorescence in each cell using Image J (Rasband, W.S., ImageJ, U. S. National 
Institutes of Health, Bethesda, Maryland, USA, http://rsb.info.nih.gov/ij/, 1997-2006).  
The area and regions of interest of cells were determined from the phase contrast 
image, and mean specific fluorescence values for each cell were determined for that 
same area in the fluorescent channel.  Data is the result of at least 25 cells from each 
treatment, selected randomly using the phase contrast channel. 
80 
 
 
 
81 
 
2.3 Results. 
Antibody and Fab preparation and binding.  Fab fragments of MAbs 
prepared by papain digestion were further purified by gel chromatography to ensure 
that only monomeric Fab proteins were used in these studies.  All the Fabs bound to 
CPV-2 and FPV capsids in ELISA (Figure 2.1), except for the CPV-specific Fab14 
which does not bind FPV (57)(Figure 2.1a).  Direct calibration ELISA was used to 
determine the affinity of binding of the 8 Fabs to CPV-2 capsids (Figure 2.2) (20).  
Seven of the Fabs showed clear binding kinetics in the assays, and their affinities were 
readily determined (Table 2.2).  Fab B showed low binding in the assays, and in the 
transfer assay showed increasing binding during the repeated transfers (Figure 2.2C), 
so that its affinity could not be calculated directly but was estimated to be around 8 x 
10-9 nM.  The binding affinities of 7 of the Fabs tested did not differ by more than 3-
fold.  The intact IgGs all showed higher avidities compared to the Fabs, as would be 
expected from their bivalent interactions (results not show). 
Neutralization of FPV and CPV by IgG and Fabs.  When tested as IgGs 7 
of the antibodies neutralized >90% of CPV infectivity at 5nM and >99% CPV 
infectivity at 25nM, while MAb 14 neutralized only 88% of the infectivity at 100 nM 
(Figure 2.3A).  FPV showed similar neutralization sensitivity, and >99% of the 
infectivity was also neutralized by 5nM of the 7 IgGs that reacted with the virus, but 
not by MAb 14 (Figure 2.3B).  When the Fabs were tested, E and F neutralized >99% 
of the viral infectivity of both CPV and FPV at 5nM or lower concentrations, while 
Fab 16 neutralized at 25nM, and Fab 6 neutralized FPV only at 100nM (Figs. 2.4).  By 
capture ELISA we determined that the capsids were present in the infectivity stocks 
used for the TCID50 titrations at concentrations of ~6 μg/ml, so that the Fab:capsid 
ratios were ~100:1 at 5 nM (data not shown).
 
 
Figure 2.1. 
Binding of Fabs for (A) CPV or (B) FPV capsids.  The Fab fragments bound were 
detected with either an anti-mouse or anti-rat horseradish peroxidase conjugated 
secondary antibody as appropriate.  Error bars show the standard error of the mean, 
comparing the results of 3 separate experiments. 
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Figure 2.2. 
Determining the binding affinities of the 8 Fabs to the CPV capsids by measuring the 
kinetics of binding, the saturated binding level, and the degree of binding when the 
Fabs were incubated with the viral antigen and then transferred to a new well after 
various times; the 30 min transfer data is shown as an example.  (A) The rate of Fab 
binding to the antigen, tested by allowing the Fabs to incubate for various times with 
the capsids before washing, then detecting with anti-mouse or anti-rat IgG HRPO 
conjugates.  (B) The saturation of binding for the 8 different Fabs, showing the 
binding when the antigen was incubated with increasing amounts of the Fabs, allowing 
the saturated binding to be estimated.  (C) The binding of each Fab in a transfer assay 
where the Fabs were incubated with the antigen for 30 min before transferring to a 
new well.  This was repeated 4 times for various lengths of time; the 30 min data is 
shown here.
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Table 2.2. 
Determination of the affinities of the Fabs examined here using the direct calibration 
ELISA method.  The three components of the analysis are given, as well as the affinity 
calculated as the dissociation constant.  We were unable to accurately determine the 
affinity of Fab B using this method.  ND = not determined. 
Antibody 
ID 
Rate of complex 
formation (Kc, s-
1) 
Calibration 
Factor (c, M) 
Transfer 
Factor (F) 
Dissociation 
constant (Kd, M) 
14 1.2 × 10-3 7.0 × 10-10 0.9 3.4 × 10-9 
15 3.4 × 10-3 1.3 × 10-9 0.7 2.1 × 10-9 
16 1.0 × 10-3 8.6 × 10-10 0.83 2.6 × 10-9 
6 1.3 × 10-3 4.8 × 10-11 0.99 3.2 × 10-9 
8 1.7 × 10-3 1 × 10-9 0.82 3.4 × 10-9 
B ND ND ND ~6.1 × 10-9 
F 1.7 × 10-3 8 × 10-9 0.39 1.5 × 10-9 
E 8.5 × 10-4 2 × 10-9 0.8 1.7 × 10-9 
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Figure 2.3. 
The neutralization of (A) CPV-2 and (B) FPV infectivity by various amounts of the 
different IgGs of the 8 different MAb tested here.  The IgGs were added to 10,000 
TCID50 of each virus at concentrations between 0 and 100 nM, incubated for 1 h at 
37°C, then the surviving virus was diluted and tested for surviving TCID50 in CRFK 
cells.  The results are shown as the surviving infectivity in each culture compared to 
the titer of the control virus.  Bars show the standard error of the mean, comparing the 
results of 3 separate experiments done on separate days.
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Figure 2.4. 
The neutralization of (A) CPV-2 and (B) FPV infectivity by the Fab fragments of the 8 
different MAbs as shown for the IgGs in Figure 2.3.  The results are shown as the 
surviving infectivity in each culture compared to the titer of the control virus.  Bars 
show the standard error of the mean, comparing the results of 3 separate experiments 
done on separate days.
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Fabs compete for receptor binding of the capsid.  The CPV-2 capsids were 
labeled with Cy2 and bound to the purified ectodomain of feline TfR in a solid phase 
assay.  All Fabs reduced capsid binding to the TfR at concentrations of 29 nM or 
greater (20 Fabs per capsid) (Figure 2.5).  Fabs E and F showed the greatest 
competition, while Fab 6 did not completely block binding even at 100nM (Figure 
2.5).  Fab B also allowed some binding at 100 Fabs per capsid, perhaps due to its 
lower affinity relative to the other Fabs (Figure 2.2 and Table 2.2). 
Fabs and viral attachment to cells.  All Fabs were able to block the binding 
and uptake of a proportion of the capsids into TRVb cells expressing the feline TfR 
when tested at Fab:capsid ratios of up to 100:1 (Figure 2.6).  However, all Fabs  
reduced binding and uptake to similar levels, and no specific distinction was seen 
between the highly neutralizing Fabs and the less or non-neutralizing Fabs. 
 
2.5 Discussion. 
Here we show that the parvovirus capsid interactions with antibodies are 
surprisingly complex and showed clear differences in viral neutralization despite the 
fact that they bind with similar affinities to most or all of the 60 sites on the capsid.  
Studies of escape mutations and competition assays have suggested that most 
antibodies generated against intact capsids recognize two dominant antigenic sites, 
described as site A near the top of the three fold axis and site B on the shoulder of that 
structure (76).  The general features of those sites are shown in Figure 2.7, where the 
residues that affect the A and B sites in previous studies are displayed, along with 
projected Fab density from radial sections of Fab-virus cryoEM reconstructions Fab 
14 bound to the A site while Fab 15 bound to the B site.  In other studies, footprints of 
these Fabs have been defined by cryoEM reconstruction techniques which confirm the 
disposition of the two binding sites (25). 
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Figure 2.5. 
Inhibition of binding of Cy2-labelled CPV-2 capsids to the feline TfR by the 8 Fabs 
tested here.  The capsids were incubated with varying amounts of Fab per capsid, and 
then added to plates coated with the purified feline TfR ectodomain, and the bound 
capsids detected using a fluorescence plate reader.  The amount of binding is shown as 
the percentage of the binding of the capsids without Fab added.  Control Fabs against 
the capsids of adeno-associated viruses types 1 and 5 were tested at only 100 Fabs per 
capsid.  The results are shown as the mean and standard error of three separate 
experiments.
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Figure 2.6. 
Competition by Fabs for cell binding and uptake.  CPV-2 capsids were incubated with 
varying amounts of the Fabs for 1 h at 37°C, then bound to TRVb cells expressing the 
feline TfR. 
(A) Representative micrographs are shown for the no Fab control, and the Fabs against 
the A site (Fab 14) or the B site  (Fab F). 
(B) Total average cell-associated fluorescence (per cell) was determined for at least 20 
cells at each concentration.  Results are plotted as a percentage of the CPV bound to 
cells in the absence of any added Fabs.  The control anti-AAV Fabs were tested at 100 
Fabs/capsid.
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 Figure 2.7. 
A roadmap showing the location of surface residues of CPV-2 that affect the binding 
of the different antibodies to the capsid structures.  A single asymmetric unit of the 
capsid is shown.  Two antigenic sites have been previously defined, and designated as 
(A) and (B) through the analysis of mutations that affected antibody binding or by 
cross-competition.  Residues that affect antibody binding to some A-site antibodies are 
shown in red, and those affecting B-site antibodies are shown in blue.  CryoEM 
density corresponding to Fab14 as bound to the A site and Fab15 as it interacts with 
the B site are projected to the surface of the virion and indicated as red (Fab14) or blue 
(Fab15).  The projection of Fab density obtained from virus-Fab complex shows the A 
and B sites as previously described, but with some possible overlap between the 
antibodies binding to the two sites (25). 
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Although all 8 IgGs neutralized the viruses only two of the Fabs neutralized 
efficiently, and another was intermediate in neutralizing ability.  Both neutralizing and 
non-neutralizing Fabs bound to the B site of the capsids, showing that neutralization  
depends on specific interactions of the Fabs with the capsid rather than being a result 
of simple Fab attachment to a particular site, and the neutralizing and non-neutralizing 
antibodies must therefore affect the cell infection processes differently.  None of the A 
site Fabs tested here efficiently neutralized the virus. 
Blockade of receptor binding is often suggested as a mechanism of viral 
neutralization, and here we were able to test for this effect using the purified receptor 
in in vitro assays, and by testing for binding to the receptor on cells.  The results 
indicate that any neutralization differences due to effects on TfR binding would be 
rather subtle, since all of the Fabs inhibited binding to the purified receptor 
ectodomain when present in high enough concentrations.  However, the highly 
neutralizing Fabs (E and F) blocked capsid binding to the TfR at the non-saturating 
concentration of 25 Fab per capsid, and even blocked 80% of the binding at a ratio of 
6.25 Fab per capsid.  This suggests a mechanism of neutralization that results from a 
direct effect of small numbers of Fabs on the capsid that blocks TfR binding to the 
remaining sites on the capsid, perhaps through some allosteric change induced in the 
capsid.  However, in limited studies we have not been able to directly demonstrate any 
change in the capsid (results not shown).  The less efficiently neutralizing or non-
neutralizing Fabs also inhibited capsid binding to the feline TfR when added at higher 
concentrations, indicating that they would not have the same structural effect on the 
capsids, and that they must leave sufficient binding sites available at lower antibody 
concentrations for cell binding and endocytosis allowing infection.  The TfR is very 
efficiently taken up by clathrin-mediated endocytosis (19), and even the low affinity 
binding of the capsid to the canine TfR allows efficient infection of cells (52). 
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 The antibodies against the CPV and FPV capsids recognize only a limited 
number of structural sites (25), suggesting that those sites are particularly efficient at 
selecting high affinity antibodies and are the result of selection to allow the most 
efficient replication and transmission in the presence of antibodies.  The capsid 
structures of the parvoviruses infecting vertebrates show a variety of prominent 
regions at or surrounding the threefold spikes (9, 30, 43, 51, 84, 90), and epitopes that 
have been mapped mostly fall on those structures (14, 39, 76, 89).  Insect parvoviruses 
are not under antibody selection, and have smoother surfaces (3, 71), suggesting that 
the prominent structures benefit the vertebrate viruses when targeted by antibodies, 
perhaps because the limited number of sites inducing high affinity antibodies allows 
them to regulate the effects of the antibody binding during infection. 
What selects for changes in the viral antigenic structure?  Although natural 
antigenic variants have been seen among the CPV- and FPV-like viruses, most of 
those changes simultaneously alter TfR receptor binding (27, 29, 52), and in this case 
it appears that antigenic variation is a side-effect of capsid changes that alter receptor 
binding to mediate host adaptation.  FPV and MEV have been in long association with 
their hosts and are also antigenically conserved, with only a single antigenic variant 
being identified among MEV isolates due to the change of residue 300 from Ala to Ser 
(57, 59).  The natural antigenic variants of CPV fall within both the A and B sites of 
the capsid.  The change of VP2 residue 93 from Lys to Asn during the emergence of 
CPV was required for canine TfR binding and canine host range determination, and 
that also altered antigenic site A (8, 27, 29).  That difference would not have been 
subject to selection by preexisting immunity as CPV-2 could not infect cats, so the 
selection of that site was for host range variation alone.  Some combination of the 
changes between CPV-2 and CPV-2a of VP2 residues 87, 101, 300, and 305 also 
reduced the affinity of CPV-2a binding of CPV-2a to the feline TfR (52), and allowed 
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 the CPV-2a and the more recent strains to infect cats (77).  Those changes also altered 
antigenic site B causing the loss of binding to some antibodies that bound CPV-2 and 
FPV, and creating the CPV-2a specific antigenic sites (56).  That variation also 
reduced the affinity of the virus for the feline TfR and likely determined the host range 
for cats, again making it likely that receptor binding was the most important property 
being selected. 
Other antigenic variants have emerged in the CPV-2a background; after 1983 
the change of VP2 residue 426 from Asn to Asp was found worldwide, giving the 
CPV-2b variant (56).  That mutation is still seen at various levels among dogs around 
the world, suggesting that the selection on that site prevents it becoming fixed (5, 13, 
67, 75).  Since the year 2000, viruses containing the VP2 residue 426 to Glu 
replacement have been seen in various parts of the world, and that variant is increasing 
in frequency (42, 48).  Residue 426 is within the TfR binding site, but effects of those 
mutations on TfR binding have not been described. 
Antibody and receptor binding have overlapping effects on the pathogenesis 
and epidemiology of these viruses.  Antibodies in infected and recovered animals 
protect for life against re-infection, so that the viruses are maintained in nature as a 
series of acute infections of puppies or kittens which have waning or no maternal 
immunity.  This continual turnover of the virus population allows mutations to be 
selected within the global populations of hosts over short time periods.  Host infection 
is oro-nasal, and the virus then circulates systemically to infect cells in many 
lymphoid tissues and the small intestine, and the virus is vulnerable to both mucosal 
and plasma antibodies during this process.  Ability to infect hosts with low levels of 
maternal antibodies may be a selected property of these viruses (18, 41, 62, 85).  In 
addition, although anti-viral antibodies are important for recovery from infection, 
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 some viremia continues for a short period in the presence of the developing antibody 
response (44). 
The interactions between viruses, host receptors and antibodies can be 
complex, even for the simple parvovirus capsids.  The extensive overlap between the 
TfR and antibody binding sites results in many mutations in the capsid surface that 
affect the binding of both ligands simultaneously.  The antibody-capsid interactions of 
these parvoviruses may share features with other virus-receptor-antibody interactions.  
The foot and mouth disease virus also shows overlap between the integrin binding 
sequence and antibody epitopes on the G-H loop of the virus, although the Arg-Gly-
Asp binding sequence is quite small and may be conserved while the surrounding 
epitopes can vary (15, 82).  In other cases the receptor binding and antigenic sites are 
largely distinct.  Some picornaviruses bind their receptors through a lowered region of 
the capsids (canyon), while most of the antigenic sites are on raised regions (although 
some antibodies may be able to access the receptor site) (64, 74).  For the influenza 
virus hemagglutinin the sialic acids bind in relatively conserved pockets while the 
antigenic sites are on surface regions which can readily accommodate variation (72, 
73).  In HIV the receptor binding sites on the gp120 are protected from antibody by a 
variety of strategies including overlapping carbohydrate structures and rapid 
variability, while the conserved chemokine receptor binding site is buried within the 
structure and not revealed until after CD4 binding (11, 33).  Most viruses of 
vertebrates are under strong antibody selection and many different solutions are used 
to allow their success.  Since these interactions are key to effective protective antiviral 
immunity, a better understanding of the processes involved would help in the design 
of better vaccines in the future. 
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Structure analysis of eight antibodies with variable neutralizing abilities bound to 
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 3.1 Abstract. 
The host antibody response is important for protection from and clearance of 
viral infection, yet the structures on nonenveloped viral capsids that elicit this antibody 
response are not well understood.  We have examined by cryo-electron microscopy 
and image reconstruction the binding sites of five mouse and three rat IgG Fab 
fragments on the surface of canine parvovirus and feline panleukopenia virus capsids. 
We find that these antibodies cluster to two main sites on the surface of the virus, but 
that each antibody has a unique interaction with the virus.  Many of those Fab 
footprints overlap with the binding site of transferrin receptor, the cellular receptor for 
these viruses.  This suggests that competition for receptor binding may be a 
mechanism of neutralization for these antibodies, however five Fabs do not neutralize 
infectivity despite binding the capsid with approximately full occupancy.  Structural 
differences between the Fabs that were neutralizing and those that were non-
neutralizing were not readily apparent.  These footprints also cover ~70% of the 
surface accessible areas of the capsid, and suggest that the two antigenic regions of the 
capsid may overlap and be larger than previously suggested. 
 
3.2 Introduction. 
Antibodies are specialized molecules that bind specific epitopes on viral 
proteins or other antigenic molecules, often with high affinity.  An understanding of 
the antigenic structures of viral proteins is critical for the rationale design of new anti-
viral vaccines and of gene therapy vectors, as well as furthering our understanding of 
virus neutralization (3, 27). During a viral infection the proteins of the virus will bind 
to the surface immunoglobulin on the surface of B cells.  In a naive animal those 
would be surface IgM, and the crosslinking of the receptors by the multimeric viral 
epitopes may stimulate a rapid response in the B cells, and the production of IgM.  
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 Upon continuing antigen exposure, and in the presence of T cell help, the cells will 
undergo class switching and selection, along with somatic hypermutation of antibody 
variable domain genes.  These mutations during B cell development selects for high 
affinity antibodies; however, the neutralizing ability of the antibody is not considered 
during this selection process (22).  Therefore, an understanding of viral epitopes and 
host antibody responses may aid the production of vaccines with altered epitopes 
which generate highly neutralizing antibodies (10).  Alternatively, for gene therapy 
applications, the benefit would come from the preparation of less immunogenic 
vectors that would allow re-administration of vector without mounting a large immune 
response (2, 14, 17, 29, 48). 
For mapping antigenic sites on nonenveloped viruses, much work has been 
done on the human rhinovirus 14 (HRV14) (reviewed in (32-34)).  A combination of 
structural and biochemical data demonstrated that there were four main antigenic sites 
on the virus, termed neutralizing immunogenic sites (NIms) (30, 31).  Cryoelectron 
microscopy (cryo-EM) and X-ray diffraction yielded important insight into epitopes 
that bound the antibodies and that led to neutralization.  Cryo-EM reconstructions on 
high and low neutralizing antibodies revealed that electrostatic interactions contributed 
most to epitope selection, and many more residues were important for antibody 
binding than those seen from escape mutation analysis.  Interestingly, the neutralizing 
and non-neutralizing Fabs bound to very similar areas of the capsid, and shared 
several charged residues in their epitopes, but differ in their orientation (35-37).  It 
was also shown that the orientation was determined by the charge interactions between 
the virus and antibody, and that the CDR loops of the antibody deform and intercalate 
readily into deep crevasses on the surface of the virus. 
Although many mechanisms of neutralization have been proposed, recent 
studies have suggested antibodies neutralize viruses by a simple occupancy model (3, 
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 4, 33).  This model suggests that the requirements for effective neutralization include 
antibody binding to the virus that prevents receptor binding, and the antibodies must 
bind the virus with high affinity.  The need for high affinity fits well with the 
maturation process of antibodies, and the mass of an intact IgG or IgM appears well-
suited to compete for receptor binding, even if the antibody binds elsewhere on the 
capsid.  In HRV14, one antigenic site lies further away from the receptor binding site 
but is still able to neutralize the virus (6, 7)  It has been suggested that since a single 
IgG is equal to the radius of an HRV14 virion (150 Å), IgG binding to one location 
could sterically block binding to sites elsewhere on the capsid (33).  There is however, 
no definitive consensus on how neutralization of viruses is achieved. 
Canine parvovirus is a nonenveloped virus with a 25 nm icosahedral capsid 
(40).  The capsid is composed of sixty copies of two isoforms of the same capsid 
protein, VP1 or VP2.  These proteins are identical, except that VP1 contains an 
additional 143 residues at its N-terminus.  The capsid structure has been solved to 2.9 
Å resolution, and the core structural element is β-barrel that is similar to many other 
nonenveloped viruses (40, 46).  The surface structure of this virus is composed of 
elaborate loops that connect the strands of this β-barrel.  The longest of these loops, 
the GH loop, forms a large raised region on the capsid over the 3-fold axis of 
symmetry and is referred to as the 3-fold spike.  This region of the capsid contains 
residues that are important for receptor and antibody binding (11, 38). 
The major antigenic sites on CPV have been mapped by escape mutant 
analysis, and demonstrated that most amino acid substitutions clustered to two main 
sites on the surface of the capsid that were called sites A and B.  Site A involved 
residues close to the 3-fold axis of symmetry around residues 93, 222, and 224.  Site B 
clustered closer to the 2-fold axis and involved residues 299, 300, and 302 (38).  One 
site B antibody, MAb 8, has been directly visualized binding to CPV by cryo-EM and 
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 image reconstructions of capsid-Fab complexes, and a pseudo atomic resolution co-
structure was generated by fitting of the solved CPV capsid and a homology model of 
the Fab structure (45).  The epitope defined by the antibody footprint largely 
confirmed the results from the escape mutation analysis of site B antibodies.  The N-
terminus of VP2, residues 1-23, as well as other residues on the surface of the capsid 
(residues 91, 172, 283, 297, and 498, 549, 573) have been reported as a B-cell epitope 
(16, 19). 
CPV binds and uses the transferrin receptor (TfR) to infect cells.  TfR is a type 
II membrane protein that is present as a homodimer on the surface of cells (8).  CPV 
interacts with residues in the apical domain of TfR, and residues important for the 
specific binding of the canine TfR have been mapped by natural variation and by site 
directed mutagenesis and include residues 93, 300, 305, and 323 (11, 13, 23).  These 
residues are present within both the A and B antigenic sites, and those are separated by 
20-30 Å on the surface of the capsid (40).  A soluble form of the feline TfR has been 
generated by recombinant baculovirus expression and the TfR-CPV complex 
visualized by cryo-EM and image reconstructions (9, 12).  That reconstruction verified 
the footprint of TfR binding on the surface of the virus, and showed that TfR makes 
extensive interactions with the viral capsid, and overlaps both sites A and site B. 
The eight antibodies studied here have been previously examined for their 
ability to neutralize CPV and FPV (21).  These Fabs fragments all bound to CPV with 
similar relative affinities, as determined by solid phase binding assays.  All of the IgGs 
of these antibodies were able to neutralize CPV, but the Fabs were divided into 
neutralizing and non-neutralizing groups.  The neutralizing Fabs neutralized virus at 
<100 Fabs per capsid and directly competed with TfR for binding to CPV at lower Fab 
to capsid ratios than the non-neutralizing Fabs.  The IgGs of these antibodies all were 
neutralizing, and those may have inhibited infectivity by aggregating particles through 
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 the cross-linking of the bivalent antibody, and perhaps by the larger mass of the IgG 
compared to the Fab; two of the IgGs were previously shown to crosslink and 
aggregate capsids (47). 
In this study we present the structures for eight Fab-CPV complexes by cryo-
EM and image reconstruction.  The binding sites of the antibodies confirmed the 
general features revealed by escape mutant analysis, and showed no major changes in 
the capsids after binding, at least at the resolution of these reconstructions.  This work 
also shows that most of the surface exposed regions of the capsid appear to serve as a 
functional epitope. 
 
3.3 Materials and methods. 
Virus production and purification.  Virus production and purification were 
performed as previously described (1).  Briefly, inoculums were generated from 
transfection of Norden laboratory feline kidney cells (NLFK) with an infectious clone 
of CPV-2 or FPV (24).  NLFK cells were maintained in a 1:1 mixture of McCoy’s 5A 
and Liebovitz L15 media with 5% fetal bovine serum.  These inoculums were 
amplified by several passages in NLFK cells and then used to infect roller bottles.  At 
48 hpi, roller bottles were frozen and thawed three times and the cellular debris was 
scraped off of the walls of the bottles.  Capsids were precipitated with polyethylene 
glycol 8000 (PEG), and full and empty capsids were purified by banding on 10 to 40% 
sucrose gradients.  Capsids were passed through a Sepharose CL-4B column in 50 
mM PIPES.NaOH (pH 7.6), 150mM NaCl for further purification. 
Monoclonal antibody production, purification, and generation of Fabs. 
The production and characterization of the hybridomas used here have previously been 
described (25, 26).  MAbs and Fabs were generated according to previously published 
results (21).  Briefly, hybridomas were grown in Dulbecco’s minimal essential 
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 medium, non-essential amino acids, and 5% FBS.  These cultures were expanded and 
placed into gas permeable cell culture bags (Nexell, Irving, CA).  After culture the 
cellular debris was removed by centrifugation, the supernatant was 0.22 µm filtered 
and dialyzed into phosphate buffer in a 10 kDa cut-off membrane spiral dialysis 
cassette (Millipore, Billeria, MA).  MAbs were then purified from this supernatant by 
Protein G affinity chromatography on an AKTA FPLC (GE Healthcare, Piscataway, 
NJ).  Fabs were generated from these purified Mabs as according to manufactures 
recommended protocols (Pierce, Rockford, IL). Briefly, the protein was digested with 
papain, the Fc fragment removed by chromatography on protein A, and the 
monomeric Fab was isolated by chromatography on Sepahdex G100. 
Sequencing of variable domains of antibodies.  mRNA from hybridomas 
were purified using the RNeasy purification kit (Qiagen, Valencia, CA).  This mRNA 
was either further processed immediately, or aliquoted and stored at -80°C until used.  
cDNA and amplified products were generated using the one-step RT-PCR kit 
(Invitrogen, Carlsbad, CA).  Primers were designed for variable domain amplification 
using mouse IgG database (MRC Center for protein engineering, http://www.mrc-
cpe.cam.ac.uk).  Rat IgG primers were designed from degenerate primers of published 
sequences. PCR products were then cloned into pGEM T-easy (Promega, Madison, 
WI).  Plasmid inserts were then sequenced using T7 or SP6 primers.  The variable 
sequences of MAb 8 and MAb 14 have been previously described, and these 
sequences were re-determined in this study (45, 47).  The heavy chain of antibody 6 
proved refractory to sequencing and was not determined. 
Data collection and cryo-EM reconstruction.  Purified Fab molecules were 
incubated with virus at room temperature for 1 h at a ratio of four Fab molecules per 
potential binding site on the virus (240:1).  Small aliquots of this mixture were applied 
to carbon-coated grids and frozen in liquid ethane at -186°C.  Electron micrographs 
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 were recorded on Kodak SO-163 film by using a Phillips CM300 FEG microscope.  
Micrographs were digitized with a Zeiss PHODIS microdensitometer at 7-micron 
intervals.  The scans were averaged in boxes of 2 × 2 pixels.  The final averaged pixel 
size was 3.11 Å.  Particles were selected and corrected for contrast transfer function of 
the microscope using the program RobEM (http://cryo-EM.ucsd.edu/programs.shtm). 
The EM reconstruction processes were performed using icosahedral averaging with 
the programs EMPFT and EM3DR 
(http://bilbo.bio.purdue.edu/~baker/programs/programs.html).  The cryo-EM density 
of native canine parvovirus was used as an initial starting structure.  The final 
resolution was estimated by using maps of the reconstructed cryo-EM density 
representing the viral capsid between radii 70 and 140 Å and then determining where 
the Fourier shell correlation fell below 0.5 using the CUTPIFMAP, FFT, and 
EMRESOL programs written by Chuan Xiao 
(http://bilbo.bio.purdue.edu/~viruswww/Rossmann _home/river_programs/).  The 
same cryo-EM reconstruction procedure was used for each complex and for a 
reconstruction of the native virus. 
Crystallization of Fab 14 and structural solution.  Fab14 was crystallized in 
25% PEG 5K and 0.1 M HEPES (pH 7.5). It was in space group C2, with the unit cell 
parameters a = 168.604, b= 39.885, c= 70.745, and α = 94.58°, with one molecule 
(one heavy chain and one light chain fragment) per asymmetrical unit. Molecular 
replacement using 12E8 structure (Protein Data Bank (PDB) 12E8) as a search model 
found one solution with R factor of 0.497 and a correlation coefficient of 0.425. 
Further rigid body refinement improved the R factor to 0.473. The Fab14 structure 
was refined at 2.5Å, with Rworking factor of 0.232, and Rfree factor of 0.278. 
Structure and homology models for Fab.   For each Fab, the amino acid 
sequence corresponding to the variable domain (VL and VH) was submitted to Web 
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Antibody Modeling (http://antibody.bath.ac.uk/) in order to obtain a 3-D homology 
model.  The resulting 3-D model was substituted for the variable domain of a mouse 
antibody fragment (1AIH) to create a homology model.  
Difference map and fitting the Fab structure into the cryo-EM densities.  
The program EMfit was used to calibrate the exact magnification of each of the cryo-
EM reconstructions of virus complexed with Fab by comparing it with a map derived 
from the X-ray crystallographically determined coordinates of CPV or FPV (PDB 
accession numbers 1C8D and 1FPV, respectively).  A difference map was calculated 
for each virus-Fab complex by setting to zero the density within a radius of 3Å 
surrounding each atom in the virus X-ray structure.  The crystal structure of Fab 14, or 
a homology model of Fab was fitted into the difference map and each fitting was 
refined using the program EMfit 
(http://bilbo.bio.purdue.edu/~viruswww/Rossmann_home/softwares/emfit.php). 
For Fab 6, the weighting factor for steric collisions was set to 0 in order to refine the 
fit.  Residues in the virus-Fab interface were identified as those in CPV or FPV that 
had any atoms less than 4.0Å from any atom in the fitted Fab structure.  The buried 
surface area was calculated using CCP4 programs areaimol and surface 
(http://www.ccp4.ac.uk/html/areaimol.html). 
 
3.4 Results. 
Cryo-EM structures and fitting of Fab structures into the cryo-EM 
density to determine the interactions.  Cryo-EM reconstructions were determined 
for complexes between the virus capsids and each of 8 different Fabs generated from 
MAbs (Figure 3.1)(Table 3.1).  FPV was used for all reconstructions, except for Fab 
14, which only binds to CPV (25).  For seven of the reconstructions, the cryo-EM 
density corresponding to Fab was approximately equal in magnitude to that of the 
Figure 3.1. 
Cryo-EM and image reconstructions of eight monoclonal antibodies against FPV and 
CPV.  FPV was used for all reconstructions, except for Fab14, which only binds CPV. 
For each antibody, the cryo-EM reconstruction is shown on the top and the antibody 
footprint on the asymmetric unit is shown on the bottom.  For the footprint, the capsid 
residues involved in binding are highlighted and outlined in black.  Site A antibodies 
are shown in red, and site B antibodies are shown in blue. 
 
124 
  
125 
Table 3.1. 
Monoclonal antibodies used to generate FAb for the structural studies. 
 
Antibody Source Epitope Specificity 
14 Mouse A CPV only 
B Rat A CPV and FPV 
8 Mouse A CPV and FPV 
15 Mouse B CPV and FPV 
16 Mouse B CPV and FPV 
E Rat B CPV and FPV 
F Rat B CPV and FPV 
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virion capsid, indicating that most of the 60 possible Fab binding sites was occupied. 
For the complex of Fab 6 and FPV a lower Fab density was seen, as the Fab bound 
very close to the threefold axis of symmetry and steric hindrances between the bound 
Fabs allowed only 1 Fab to bind per 3-fold axis.  The resolutions of the 
reconstructions varied from 8 to 18Å, correlating to the number of particles used for 
each reconstruction. 
In order to more accurately determine antibody footprints on the virus, 
pseudoatomic structures were generated.  Using the known X-ray crystal structure of 
CPV or FPV (1C8D and 1FPV respectively) the density corresponding to virus was 
removed from each cryo-EM map (see methods).  This provided a Fab difference 
density map to fit the Fab structures into.  Since only the X-ray structure of Fab 14. 
was solved, homology models for the remaining 7 antibodies were built, based on the 
sequences of the variable domains (see materials and methods).  To verify the 
usefulness of these homology models, the structure of the homology model of Fab 14 
obtained from the variable domain sequences was compared to the crystal structure of 
Fab 14.  These were both seen to be in good general agreement (data not shown).  The 
placement of each homology model into the electron density difference map was 
refined using EMfit. No visible elbow angle change was noticed between the EM 
structure and the crystal structure of the fitted Fab 14. 
The structure of CPV (1C8D) was fitted into the corresponding virus cryo-EM 
density by superimposing the icosahedral symmetry elements.  Antibody footprints 
were then assigned based on proximity of atoms on the surface of the virus and Fabs, 
where atoms within 4.0 Å of each other were considered interacting (Figure 3.1).  The 
buried surface areas for these Fabs ranged from 700-900Å2.  A mentioned above, for 
the Fab 6 and FPV complex steric interference resulted in only one Fab binding per 
each threefold-spike, so that only 20 Fabs were bound overall.  
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In the reconstructions of complexes with Fab 14, B, 8, 15 and 16, the Fab 
structure extends away from the surface of the virus with the long axes in a radial 
direction (Figure 3.1).  The Fab portion of an entire IgG structure was fitted into each 
reconstruction to assess whether bivalent binding was possible across the icosahedral 
two fold axes, but in each case the Fab was oriented in such a way that bivalent 
binding is not possible.  However, the fitting of full-length IgG showed there was 
sufficient length to the IgG flexible loops connecting the two Fab arms to allow 
crosslinking of particles.  This is consistent with previously published reports for 
antibodies 14 and 8, which showed crosslinking of viral particles (47).  For Fab E and 
F, the Fab structure is less upright, leaning into the surface of the capsid, making 
contact between heavy chain framework residues and the virus surface.  Thus the Fab 
is oriented such that the long axes extend at lower angle relative to the surface of the 
virus, so each Fab blocks access to another region of the capsid surface that is not 
actually within the footprint of that Fab. 
Characterization of the antigenic surface of the virus.  Previously published 
reports identified two main antigenic sites on the virus, by escape mutational analysis.  
Site A mapped close to the 3-fold axis of symmetry and involved residues 93, 222, and 
224, while Site B was further down the spike and involved residues 299, 300, and 302.  
To compare how accurately the escape mutant analysis predicted the actual antibody 
footprints, the shared areas of each antibody were displayed on the asymmetric unit 
(Figure 3.2).  These footprints were found to be in good general agreement with the 
escape mutants, and also identified several more residues in the shared antibody 
footprint.  For site A, these include residues 93, 222, 224, 225, 323, 423, 425-428, 
while site B had residues 298-302, and 387. 
Nature of antigenic sites.  The footprints of the antibodies covered a total of 
~70% of the capsid surface (Figure 3.3).  The combined footprint can also be 
 Figure 3.2. 
The shared binding domains of site A and B antibodies, displayed on one asymmetric 
unit.  Site A is colored in blue and site B is colored in red. 
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Figure 3.3. 
The combined binding domain of A and B site antibodies displayed on one 
asymmetric unit.  Site A antibodies are displayed in red, and site B are displayed in 
blue. 
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displayed according to a radial density map (Figure 3.4).  These footprints were 
examined for their properties, including surface charge, hydrophobicity and 
hydrophilicity.  Amino acid identity of entire CPV surface included 42% polar, 27% 
charged, 32% hydrophobic amino acids; within the footprints of the B-site binding Fab 
the exposed residues were 52% polar, 23% charged, 24% hydrophobic; within the A 
site they were 46% polar, 20% charged, 34% hydrophobic. 
 
3.5 Discussion. 
In this study we present the complex interactions of eight antibody Fab 
fragments with FPV or CPV.  We show that each of these eight Fab fragments make a 
unique interaction with the viral surface, but that there is clustering of these footprints 
to specific parts of the capsid.  Previously, escape mutation analysis has shown that 
binding of these antibodies are controlled by a specific set of residues on the surface of 
the virus (38).  Site A was shown to be on the three-fold spike and binding of 
antibodies to this region was controlled by residues 93, 222, and 224.   
All of the site A antibodies share these residues in their combined footprint, as 
well as residues 225, 323, 423, 425-428 (Figure 3.2).  Site B mapped further from the 
3-fold spike and binding to this region was controlled by residues 299, 300, and 302.   
The combined site B antibody footprint contained these residues as well as 298, 301, 
302, and 387 (Figure 3.2).  It is not known whether all of these shared residues 
contribute to the binding of these antibodies, or are included due to their close 
proximity to critical residues.  Also possible is that mutation of these additional 
residues would result in non-viable viruses that would not be amplified during escape 
mutant analysis. 
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Figure 3.4. 
The combined outline of the antibody footprints displayed on a radial structure of the 
asymmetric unit. Red colors denote amino acids that are further from the center of the 
capsid, while blue denotes amino acids in recessed areas of the capsid. 
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Pseudo-atomic structures were generated by fitting in known atomic resolution 
structures of CPV and Fab 14.  This method has been highly successful in determining 
virus receptor interactions for structures that are not normally able to be solved by X-
ray diffraction of complex crystals (5, 18, 28, 41).  For the other seven Fabs whose 
crystal structure was not determined, we used homology modeling to estimate the 
structure of the variable domain of these antibodies (44).  This method was validated 
by a comparison of the structure of variable domains of the crystal structure of Fab14 
and the predicted homology model.  This method was useful, as it was not practical to 
crystallize and solve atomic resolution structures for all eight antibodies. 
The objective of this study was to further understand the structural features that 
contribute to antibody selection.  It is becoming apparent that the most tractable 
method for studying virus-antibody epitope is through a structural approach, and more 
recent work is beginning to define these interactions (reviewed in (33)).  By 
examining eight monoclonal antibodies, we hoped to elucidate common structural 
features that comprise viral epitopes.  No distinct features were obvious in the two 
antigenic sites with respect to charge or hydrophobicity.  Also, no specific 
arrangement of charged or hydrophobic residues were readily seen that could explain 
the preferential use of site A and B as epitopes.  Site A and B antibodies share 
common area binding domains with each other, all antibodies clearly have unique 
interactions with the capsid.  It appears that the combined antibody sites represent the 
surface area that is accessible to antibody binding (Figure 3.4).  The remaining sites on 
the virus are in either recessed canyons such as the 2-fold dimple, or large protruding 
domains, such as the 5-fold cylinder. 
A secondary goal was to gain further insight into the structural basis of 
antibody neutralization.  Previous studies have examined the ability of these 
antibodies to neutralize CPV and FPV (21).  All intact IgGs were able to neutralize 
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 CPV and FPV, whereas only 3 Fab fragments of these IgGs were able to neutralize 
either virus.  Rat antibodies F and E were shown to be neutralizing at ~<100 Fabs per 
capsid, and one mouse antibody (Fab 16) neutralized at ~500 Fabs per capsid. All of 
these Fabs had similar affinities, suggesting that the epitope may be important for 
determining neutralization.  The three neutralizing Fabs are site B antibodies, yet a 
comparison of these neutralizing footprints compared to non-neutralizing footprints do 
not yield any obvious insight into the mechanism of neutralization by these antibodies.  
All of these Fabs bound with similar affinities and similar levels of occupancy, except 
Fab 6, which bound once per three-fold axis.  The angle of antibody binding for Fab F 
and E are more skewed across the two fold axis, and this may occlude critical residues 
that the other antibodies do not block (Figure 3.1).  Both antigenic sites overlap the 
receptor binding domain, as determined by Cryo-EM and image reconstructions (9, 
20).  Structural asymmetry in CPV has been proposed recently, and this may help 
explain how antibody F and E neutralize CPV.  Both of these antibodies lean across 
the two-fold axis and therefore have the possibility to occlude a unique site on CPV 
that antibodies may otherwise not be able to bind.  Therefore, if CPV were to bind to 
this unique vertex, then only antibody E and F would effectively compete with TfR for 
binding to capsids.  Other antibodies are able to less effectively compete with TfR 
binding and indicates that TfR may bind regions outside this asymmetric site, or 
regions of TfR protrude outside of this site. However, these antibodies are non-
neutralizing and therefore must be less effective in blocking TfR binding. 
What are the highest affinity antibody binding areas on parvovirus capsids, and 
are these selected for during B-cell maturation?  Since the hybridomas used in this 
study were generated from mice and rats that had been repeatedly immunized with 
antigen, the IgGs used here represent the high affinity response of the vertebrate 
immune system.  It is therefore possible common overlap regions of the A and B sites 
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 could represent the highest affinity sites on the virus.  Another possibility is that 
antibodies selection is confined to areas around site A and B due to the usage of 
particular variable domain gene segments during somatic recombination.  It has been 
demonstrated that viral infection will stimulate antibody production using a limited 
subset of antibody variable domain gene segments, and this may limit the antibody 
response toparticular regions of capsids (15, 39, 42, 43).  Phage display or similar 
studies would be instrumental in determining whether other high affinity sites are 
available on the capsid.  Conversely, it would also be of interest to examine early 
response (and presumably lower affinity) IgM Fab fragments, to see if they displayed 
significantly different antigenic sites than the affinity matured IgGs studied here.  
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 4.1 Abstract. 
Parvovirus capsids are assembled from multiple forms of a single protein, and 
are quite stable structurally.  However, in order to infect cells, conformational 
plasticity of the capsid is required and this likely involves the exposure of structures 
that are buried within the structural models. The presence of functional asymmetry in 
the otherwise icosahedral capsid has also been proposed. Here we examined the 
protein composition of canine parvovirus capsids, and evaluated their structural 
variation and permeability by protease sensitivity, spectrofluorometry, and negative 
staining electron microscopy.  Additional protein forms identified included an 
apparent smaller variant of the virus protein (VP) 1, and a small proportion of a 
cleaved form of VP2.  Only a small percentage of the proteins in intact capsids were 
cleaved by any of the proteases tested.  The capsid susceptibility to proteolysis varied 
with temperature but new cleavages were not revealed.  No global change in the 
capsid structure was observed by analysis of Trp fluorescence when capsids were 
heated between 40° and 60°C.  However, increased polarity of empty capsids was 
indicated by bis-ANS binding, something not seen for DNA-containing capsids.  
Removal of calcium with EGTA or exposure to pHs as low as 5.0 had little effect on 
the structure, but at pH 4.0 changes were revealed by proteinase K digestion.  
Exposure of viral DNA to the external environment started above 50°C.  Some 
negative stains showed increased permeability of empty capsids at higher 
temperatures, but no effects were seen after EGTA treatment. 
 
4.2 Introduction. 
 The capsids of animal viruses are molecular machines that serve many 
functions in the viral life cycle.  For parvoviruses, a small number of overlapping 
proteins make up the capsids and serve multiple intricate functions. These include 
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 protecting the genome from the environment, interacting with host receptors and 
antibodies, targeting the particle to the correct cells and tissues, controlling the process 
of cell uptake, trafficking the genome to the nucleus during cell infection, and 
releasing their ssDNA at the correct cellular location for replication.  The canine 
parvovirus (CPV) capsid has been considered to have a superficially simple structure 
which is assembled from 60 copies of a combination of two proteins, VP1 (84 kDa) 
and VP2 (67 kDa) (32, 53).  About 90% of the protein in the capsid is VP2, and 10% 
is VP1 which contains the entire VP2 sequence and 143 additional residues at its N 
terminus (43). The 5-6 copies of the VP1 N-terminal sequence are sequestered from 
antibody binding and their distribution within the T=1 icosahedron is unknown (31).  
In full (DNA containing) capsids, some VP2 proteins can be converted to the ~63 kDa 
VP3 by proteolytic cleavage of approximately 19 amino acids from the N-terminus 
(57). This cleavage is not seen in empty (no DNA) capsids.  CPV is transmitted by the 
fecal-oral route, and the viruses are stable in the intestinal contents and feces of 
animals and may persist in the environment for days or weeks before infecting another 
host (14). 
 The parvoviruses related to CPV include three variants which have >99% 
sequence  identity, but which differ in host range, receptor binding, and antigenic 
structure (20, 49).  The ancestral feline panleukopenia virus (FPV) of cats mutated to 
create the original strain of CPV, termed CPV type-2 (CPV-2) which spread around 
the world in 1978 (40).  A variant strain called CPV type-2a (CPV-2a) replaced CPV-
2 world-wide during 1979 and 1980, and contained changes of VP2 residues 87, 101, 
300 and 305 (35, 37, 41).  The CPV-2a variant is antigenically different from CPV-2, 
has an altered host range for cats (52), and has a reduced binding to the feline 
transferrin receptor (TfR) (30).  Since 1980 a variety of additional mutants have arisen 
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 in the CPV-2a background, including changes of VP2 residues 426 (Asn to Asp; then 
from Asp to Glu), and 297 (Ser to Ala) (4, 36).  
 The primary cell receptor for FPV and CPV is the host TfR (33).  CPV and 
FPV capsids both bind the feline TfR, while CPV capsids also bind the canine TfR, 
and that binding is a primary determinant of canine host range (17, 19).  Canine TfR 
binding is dictated by residues in at least 3 distinct positions on the capsid surface, 
including VP2 residues 93, 299, and 323 (20, 34).  Structural studies of the feline TfR 
bound to the CPV-2 capsid defined the receptor footprint, and also indicated that the 
receptor occupied only a few of the 60 potential binding sites on the T=1 capsid (16).  
Possible reasons for the low occupancy of receptor binding might include inherent 
asymmetry of the capsid where only a limited number of binding sites are displayed, 
or structural changes in the capsid induced upon receptor binding which prevent 
further receptors from attaching.  Also, receptors initially bound to the capsid might 
sterically hinder the binding of additional TfRs, but models predict that 20-24 
receptors should still be able to bind to a capsid. 
 The VP1 and VP2 contain a common core β-barrel structure, where the capsid 
surface is formed by large loops inserted between some of the β-strands. Prominent 
surface features include distinct depressions at the twofold axes of icosahedral 
symmetry and surrounding the fivefold axes, and a raised region around the threefold 
axes containing the binding sites for canine or feline TfR as well as antibodies (16, 49, 
58).  Pores with ~10 Å diameter at the fivefold axes of symmetry are each surrounded 
by a cylinder made up of 5 β-ribbons.  The pores are hypothesized to allow exposure 
of the 5’-end of the viral DNA outside the capsid after DNA packaging (10), and also 
seem to promote the exposure of the VP2 N-termini in full (i.e. DNA containing) 
particles (8, 57).  
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  The dynamic properties, flexibility, and alternative structures of viral proteins 
are important for their various functions. Some type of activation has been shown to 
be required by many viruses for them to become infectious.  Triggers that control 
infectivity may include receptor binding, proteolysis of viral proteins, exposure to low 
pH, removal of ions bound within the capsid structure, or specific rearrangement of 
capsid bonds (such as disulfide bonds) (21, 48).  These triggers and the resulting 
changes in capsid structure can control virus uptake into the cell, allow membrane 
penetration or fusion, control correct trafficking within the endosomal system, and/or 
determine the success of cytoplasmic trafficking or nuclear delivery (27, 47). 
 Structural comparisons of CPV, FPV, and host range variants of those viruses 
revealed that many of the host range-determining differences were due to altered 
configurations of hydrogen bonds, with only subtle changes in the overall capsid 
protein structures (2, 23).  However, those changes clearly affect canine TfR binding 
and in some cases also modify the binding of specific antibodies (15, 30).  Their 
significant functional effects might therefore be the result of alterations in the 
flexibility of key capsid structures that control receptor or antibody binding (2, 15, 
49). 
 Crystallography studies have shown some flexibility or altered structures of the 
CPV and FPV capsid proteins when exposed to low pH or after removal of bound Ca2+ 
ions (45).  In CPV-2 capsids two Ca2+ ions are coordinated by clusters of Asp and His 
residues, and a third Ca2+ binding site is present in FPV and probably CPV-2a (45).  
Those ions are located at the interfaces between the protein subunits and stabilize 
certain capsid loops (45).  Equivalent ion binding sites are not seen in the same 
positions of capsids of related parvoviruses, such as the minute virus of  mice (MVM) 
(1, 24).  At pHs 6.2 or 5.5 the capsids exhibit only relatively minor structural changes, 
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 with the greatest effect being an increased flexibility of a surface loop between VP2 
residues 359 and 372, in part due to the release of the Ca2+ (45). 
In many parvoviruses the VP1 unique sequence contains a phospholipase A2 
(PLA2) enzyme domain that is required for successful infection.  This domain is 
sequestered in the capsid but becomes exposed during cellular uptake and infection, or 
after heating to temperatures above 45°C in vitro (9, 56, 61).  The PLA2 likely 
modifies the endosomal membrane to facilitate particle release during infection (12, 
50).  The VP1 N-terminal sequences also contain basic sequences that resemble 
classical importin-dependent nuclear localization sequences (NLS) which would also 
need to be exposed in the cytoplasm (55). 
 Here we use a variety of methods to examine the structural variability of CPV 
and related virus capsids, analyzing both wild type capsids and those of specific 
mutants that affect antibody or TfR binding.  The capsids were in general very stable, 
but low levels of structural variability were detected under certain conditions by broad 
activity proteinase and by probes for protein polarity.  At increased temperatures 
negative stains showed increased penetration of empty capsids and viral DNA became 
exposed under conditions where the capsids otherwise remained intact. Minor amounts 
of previously unrecognized capsid protein forms were also identified within the viral 
capsids.  
  
4.3 Materials and Methods. 
 Viruses, cells, and proteins.  Viruses include the prototype isolates of CPV 
type-2 (CPV-2) (CPV-d), FPV (FPV-b) and CPV-2b (CPV-39) (19, 35) as well as 
mutations with VP2 residue 297 changed from Ser to Ala (FPV S297A, CPV-2 
S297A, or CPV-2b S297A), or CPV-2 with VP2 residue 299 changed from Gly to Glu 
(CPV-2 G299E), or residue 300 changed from Ala to Asp (CPV-2 A300D).  Viruses 
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 were isolated from infectious plasmid clones and grown in feline NLFK cells in a 1:1 
mixture of McCoy’s 5A and Liebovitz L15 media with 5% fetal bovine serum (35). 
 Capsids were in most cases prepared and purified as reported previously (2). In 
short, virus was precipitated with polyethylene glycol 8000 (PEG), and full and empty 
capsids were purified by banding on 10 to 40% sucrose gradients.  Capsids were 
passed through a Sepharose CL-4B column in 50 mM PIPES.NaOH (pH 7.6), 150mM 
NaCl to remove contaminating proteins and loosely associated peptides.  In an 
alternative method capsids were purified from infected cells by banding in step 
gradients of Iodixanol (Optiprep, Axis Shield, Oslo, Norway) (11).  For the Iodixanol 
method cells were infected and incubated for 2 days, and then scraped into 0.15M 
NaCl, 50 mM Tris HCl (pH 7.5) after the initial media had been removed. After 
freezing and thawing 3 times and 50 U/ml of Benzonase was added and debris pelleted 
for 20 min at 30,000 ×g.  Capsids in the supernatant were then banded in step 
gradients of 15, 30, 45 and 60% of Iodixanol at 110,000 ×g for 6.5h at 25°C.  The 
virus-containing band was passed through a G100 column, and then separated into full 
and empty capsid fractions by a linear gradient of 10% to 30% glycerol at 83,000 ×g 
for 4.5h at 25°C.  Particles were passed through Sephadex G100 and Sepharose CL-
4B columns in 50 mM PIPES.NaOH (pH 7.6), 150mM NaCl, and virus concentration 
determined by the micro BCA assay (Pierce, Rockford, IL). 
 The relative infectivities of the purified full capsid preparations were 
calculated from the viral genomes per capsid, compared to the infectious titers, and the 
effects of purification determined by comparing virus in tissue culture medium with 
the purified full capsids.  DNA genome copy numbers were determined by 
quantitative PCR (Applied Biosystems, Foster City, CA).  Primers were designed to 
bind to a conserved region in the viral genome between nts. 1039 and 1114 of the viral 
genome (encoding NS1).  Absolute copy numbers were inferred from standard curves 
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of linearized plasmids containing the CPV sequence, and analyzed using a StepOne 
machine (Applied Biosystems, Foster City, CA).  Infectious titers were determined by 
TCID50 analysis (60).   
 The ectodomains of the feline and canine TfRs were purified after baculovirus 
expression as described previously (18, 30).  The isolation and purification of MAbs F 
and 15 has been described previously (28, 38, 39).   
 Proteolytic analysis of CPV capsids.  Proteases tested included trypsin, 
thermolysin, proteinase K, subtilisin, bromelin, and papain (all from Sigma, St. Louis, 
MO).  Proteases were kept at -80°C in their respective storage buffers, and diluted in 
reaction buffer immediately before each experiment (Table 4.1).  Protease activities 
under various buffer, temperature, pH, or EGTA conditions were calibrated with the 
Quanticleave assay with FITC-labeled casein (Pierce, Rockford, IL), using a 
fluorescence plate reader (Tecan Safire, Durham, NC).  Most assays were conducted 
using proteinase K, and the amounts required to give equivalent activities were:  21°C 
= × 1.51; 37°C = × 1; 45°C = × 0.87; 55°C = × 0.81; pH 7.6 = × 1; pH 6.0 = × 1.92; 
pH 5.0 = × 3.65; pH 4.0 = × 7.7.  Proteinase K activity was not affected by addition of 
EGTA over the time of the experiment. 
Analysis of proteins, cleavage sites and comparison of different viruses.  
Capsid sensitivity to proteinase K was tested in the presence of 0 to 50 mM EGTA, or 
at 21, 37, 45, 55°C, or at pHs 7.6, 6.0, 5.0, 4.0.  After incubation with proteinase K, 
Laemmli sample buffer with an excess of specific protease inhibitor was added and 
samples were placed in a boiling water bath for 5 min.  Samples were analyzed in 10% 
acrylamide gels, stained with Coomassie blue G-250 (Pierce, Rockford, IL) and 
imaged (Syngene, Frederick, MD).  To determine the effects of specific ligands bound 
to the capsids on the capsid proteolysis patterns, purified feline or canine TfR  
 
Table 4.1. 
Conditions used for storage, reaction and inhibition of proteases (5). 
Protease Specificity Storage buffer Dilution buffer Inhibitor 
used 
Proteinase 
K 
Hydrophobic 
aliphatics and 
aromatics 
50mM Tris-
HCl (pH 8), 5 
mM CaCl2 
50mM Tris-HCl 
(pH 8), 5 mM 
CaCl2 
PMSF 
Papain broad 
specificity, 
hydrophobics 
(P2), not valine 
(P1) 
50 mM Tris-
HCl (pH 8) 
50 mM Tris-HCl 
(pH 8) 
Sigma 
protease 
inhibitor*
Trypsin Lys, Arg 1mM HCl 50mM Tris-HCl 
(pH 8) 
PMSF 
Thermolys
in 
Bulky 
Hydrophobics 
20 mM CaCl2 50mM Tris-HCl 
(pH 8), 5 mM 
CaCl2 
EDTA 
Subtisilin Most 50 mM Tris-
HCl (pH 8) 
50 mM Tris-HCl 
(pH 8) 
PMSF 
Bromelain Nonspecific 50 mM Tris-
HCl (pH 8) 
50 mM Tris-HCl 
(pH 8) 
TPCK 
* Sigma protease inhibitior contains AEBSF, pepstatinA, E-64, bestatin, leupeptin, and aprotinin 
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ectodomains or Fabs of MAbs F or 15 were incubated with the capsids for 1 hr at 
37°C, and then the mixtures treated with proteases at 37°C and analyzed as above. 
To determine VP3 N-terminal sequences after proteinase digestions, proteins 
were transferred to 0.22 µm PVDF membranes (Immobilon Psq, Millipore, Billeria, 
MA), and N-terminal sequenced (Alphalyse, Palo Alto, CA).  Antibodies used for 
Western blotting included mouse antisera raised against peptides containing VP2 
residues 222-238, 292-310, 387-398, or 508-522 which had been conjugated to 
keyhole limpet hemocyanin.  The N-terminal region of VP1 was detected with MAb 
S2D3 recognizing VP1 residues 2-11 (56).   
Identification of proteolytic products in solution or from SDS-PAGE bands 
was conducted using both electrospray and MALDI ionization to minimize detection 
bias and increase coverage in mapping experiments.  Electrospray instrumentation 
included an Agilent XCT Plus (Agilent Technologies; Santa Clara, CA), Bruker 
micrOTOF LC (Bruker Daltonik GmbH; Bremen, DEU), and Waters QToF Premier 
(Waters Corp.; Milford, MA), all interfaced with reverse-phase HPLC (C18: 
Phenomenex Inc.; Torrance, CA).  MALDI analysis was performed with a variety of 
sample/matrix ratios and both sinapinic acid and α-Cyano-4-hydroxycinnamic acid, 
using a Bruker BiFlex III.  Identification of protein bands involved in-gel protease 
digestion followed by mass analysis as above.  A detailed protocol for in-gel 
proteolysis has been previously described (25).  
 Spectrofluorometric analysis of capsid stability and conformation.  Empty 
or full capsids were concentrated to 0.5 μM in Millipore Amicon Ultra 100 kDa cutoff 
filters (Millipore, Billerica, MA) in 50 mM PIPES.NaOH (pH 7.6), 150mM NaCl.  
Assays were carried out using a Cary Eclipse spectrofluorometer (Varian, Palo Alto, 
CA) with a 1 cm path length.  To analyze Trp fluorescence, samples were excited at 
295 nm and emissions scanned from 310 to 400 nm or kept fixed at 331 nm (Ex/Em 
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 bandwidth: 5 nm).  Capsids were monitored at temperatures between 20 and 77°C.  
Capsids were also monitored by incubating with 3 μM bis-1-anilino-8-naphthalene 
sulfonate (bis-ANS) (Invitrogen, Carlsbad, CA) under various conditions. Samples 
were excited at 395 nm (bandwidth 5 nm) and the emission read at 500 nm (bandwidth 
10 nm), and bis-ANS with no added protein was used as a background.  The effect of 
low pH on virus capsids was examined by titrating the sample pH with 0.1N HCl.  The 
effect of ligand binding on capsid structure were determined using purified feline or 
canine TfR (at a molar ratio of 30 TfR dimers per capsid) or antibody Fabs (at a molar 
ratio of 60 molecules per capsid). Capsids or purified TfRs and Fabs were also assayed 
for bis-ANS binding individually.   
Exposure of viral DNA.  Accessibility of capsid DNA were assayed using the 
dye TOTO-1 (Invitrogen, Carlsbad, CA).  Capsids (8.4 μg/ml) in various pH buffers 
were heated at temperatures up to 95°C for 10 min, cooled to room temperature, then 
TOTO-1 was added  and the samples excited at 515 nm (5 nm bandwidth) and read at 
532 nm (10 nm bandwidth).  To verify DNA exposure capsids heated to the indicated 
temperatures were cooled and then digested with 84 units of micrococcal nuclease for 
30 mins at 37oC, and stained for DNA as described above. 
 Transmission electron microscopy (TEM).  Accessibility of different metal 
salts to the interior of full and empty capsids were examined before and after heating 
to various temperatures up to 75°C, or after EGTA treatment up to 50 mM.  For most 
experiments, capsids were absorbed to carbon coated TEM grids (Electron 
Microscopy Sciences, Hatfield, PA) for 5 mins. After excess sample had been 
removed, stains were added to 5 min then blotted off.  Stains used were 2% (w/v) 
methyl amine tungstate (NanoW) in water (pH 6.8) and 1% (w/v) NiSO4 in water (pH 
7.0).  In most cases 0.1% bacitracin was added to give an even distribution on the 
grids.  Samples were visualized at 60,000 × magnification in a FEI Tecnai 12 Biotwin 
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microscope.  Ten randomly selected fields were photographed (>400 particles each 
treatment), and the percentage of capsids penetrated by the stains counted. 
 
4.4 Results. 
 Protein composition and infectivity of purified capsids.  Infectivity per 
genome was compared for viruses purified by standard PEG precipitation and sucrose 
gradient centrifugation or by iodixanol and glycerol gradients or viruses in freshly 
prepared cell culture supernatants. The infectivity of fresh capsids (1:1.3 × 10-5 
TCID50/genome copy) was similar to those of capsids purified using either PEG and 
sucrose (1:1.6 × 10-5 TCID50/genome copy) or iodixanol and glycerol (1:1 × 10-5 
TCID50/genome copy).  This demonstrates that although the viruses all had low 
infectivities in these cells, those were not altered during the purification methods used. 
 SDS-PAGE electrophoresis of all purified capsids examined showed the 
expected composition of VP1, VP2 (and VP3 in full capsids), as well as small 
amounts of previously unrecognized 70 kDa, 36.5 kDa and 33 kDa proteins (Figure 
4.1 and 4.2).  The latter proteins were each present at ~2-3 % of the VP2 protein 
concentration, but were incorporated into the capsids as they were not susceptible to 
proteolysis until significant VP2 degradation had occurred (Figures 4.1 and 4.2A).  
Western blotting and mass spectrometry indicated that these protein fragments were 
related to VP1 and VP2 (Figure 4.2B and 4.2C), and also showed that the 37 kDa 
peptide (labeled B), contained the C-terminal portion of VP2, while the 33 kDa 
peptide (labeled C) contained the VP2 N-terminal sequence (Figure 4.2). The two 
peptides represent a VP2 molecule incorporated into the capsid that has been 
hydrolyzed at one position, and between residues 270 and 292. Residue 270 is exposed 
on the interior wall of the capsid, and most of the residues between that position and 
residue 292 are buried within the capsid, while residue 292 is exposed on the capsid 
Figure 4.1. 
Digestion of full and empty particles with proteases and identification of VP3 N-
terminus. 
A) Sensitivity of the CPV-2 empty capsids to digestion with the proteases listed.  
Capsids and protease were incubated at 37° for 2 h.  Size standards are in kDa.  VP1, 
VP2 and VP3 are labeled.  Protease bands are indicated by stars.  Arrow heads labeled 
A, B and C indicate the pre-existing submolar bands detected in the purified capsids. 
B) Full capsids treated as for (A). 
C) Cleavage sites in VP2 by the different proteases in the VP2 to VP3 conversion.  
Cleavage sites were determined by N-terminal sequencing or mass spectrometry of the 
resulting VP3.  For thermolysin the major site detected is shown; another unidentified 
site was also present in lower amounts.
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Figure 4.2. 
Limited proteolysis of CPV and mapping of cleavage fragments. 
A) Protein composition of CPV-2 full capsids after incubation with 76 µg/ml of 
proteinase K at 37°C for up to 2 h.  Controls included full capsids incubated alone, 
proteinase K immediately after thawing or incubated for 2 h at 37°C.  Arrow heads 
labeled A, B and C indicate the pre-existing submolar fragments detected in the 
purified capsids.  New peptides generated by the protease treatment are indicated by 
solid arrows and are numbered.   
B) Approximate mapping of the pre-existing peptides A, B and C, as well as those 
released by proteinase K treatment (numbers refer to bands marked in (A)).  Peptides 
were identified by Western blotting with anti-peptide sera, or by mass spectrometry 
after trypsin digestion of the recovered protein band.  Precise cleavage sites have not 
yet been determined.  Boxes indicate the specific sequences recognized by anti-
peptide anti-sera. 
C) Peptide analysis of pre-existing sub-molar peptides of full capsids of CPV-2.  One 
lane of untreated full capsids was Coomassie blue stained.  Capsid proteins were 
transferred and probed with anti-capsid, or anti-peptide sera as indicated.  Anti-peptide 
antisera were made against peptides containing the VP-2 residues indicated. 
D) Western blotting for the VP-1 N-terminal peptide (residues 2-13) in full capsids 
either before or after incubating with proteinase K for 2 h at 37°C.  The arrow labeled 
2 indicates the submolar fragment that is identified as fragment 2 in (B). 
E) Capsid that were treated for 2 h with proteinase K examined in the electron 
microscope after staining with NanoW.
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surface.  No additional cleavages at similar positions appeared to be made by any of 
the proteases tested.  In full capsids, this new N-terminal fragment was split into 50% 
of a 33 kDa form and 50% of a 29 kDa form, indicating an N-terminal cleavage 
similar to VP3, even though those capsid preparations otherwise contained little VP3 
(data not shown).  The 70 kDa polypeptide has not yet been completely characterized, 
but may be a truncated form of VP1, as it reacted with antibodies binding VP2 (Figure 
4.2C).  
Screening of capsid stability by proteolytic cleavage.  All proteolytic 
enzymes tested converted most VP2 in full (but not empty) capsids into VP3 forms 
(57) (Figure 4.1B).  The exact site of cleavage was slightly different for each of the 
proteases and these were partially mapped using N-terminal sequencing of the N-
terminus of the newly generated VP3 fragment (Figure 4.1C) Although proteases were 
present in large amounts (see Figure 4.1 and 4.2), there was generally little 
degradation of the capsids during 2 hr of incubation at 37°C (Figure 4.1) and the 
proteolytic fragments generated represented only a small percentage of the total capsid 
protein.  Proteinase K was selected for more detailed studies due to its broad 
specificity and activity under the experimental conditions used. Incubating CPV-2 
virions for various times with proteinase K at 37°C in pH 7.6 gave a limited number of 
digestion products (Figure 4.2A).  Examining digested capsids by negative staining 
EM indicated that they were largely intact and that the full particles excluded the 
NanoW stain (Figure 4.2E).  After size exclusion chromatography the cleaved 
fragments remained incorporated in the capsid (results not shown).  Western blotting 
using specific peptide antibodies and mass spectrometric analysis of trypsin digested 
protein bands allowed some of the proteolytic fragments to be positioned within the 
VP1 or VP2 sequences (Figure 4.2B – 4.2D). 
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Effects of temperature on capsid structure.  Proteinase K treatment of the 
various capsids at higher temperatures demonstrated an increase in the total amount of 
digestion products, but in most cases no additional peptide fragments (Figure 4.3). 
FPV and CPV-2b capsids were more sensitive than CPV-2 capsids to digestion at 45 
and 55°C (Figure 4.3).  CPV-2 and FPV capsids with the VP2 residue 297 changed 
from Ser to Ala showed an additional peptide of 40 kDa, which was not seen in the 
wild type forms of those virus capsids, or when the mutation was in the CPV-2b 
background (Figure 4.3).  Changing CPV-2 VP2 residues 299 (Gly to Glu), or 300 
(Ala to Asp) alters the alter canine TfR binding, canine host range and antigenic 
structure of the capsid (17, 19, 23, 34), and the 300 Asp variant of CPV-2 showed loss 
of a peptide of 23 kDa that fell just below the proteinase K band (Figure 4.3).   
All viruses contain 14 Trp residues in VP2 which are mostly sequestered 
within the capsid structure (29, 59).  Tryptophan fluorescence spectra of full and 
empty CPV-2 particles under physiological conditions were indistinguishable at 22°C 
(Figure 4.4 A and B).  As the temperature was increased, the emission intensity 
decreased linearly as expected from the thermal quenching of fluorescence (3).  At 68-
70°C there was an increase and change in the emission maximum wavelength for both 
empty and full capsid particles, indicating that Trp residues were exposed during 
particle disintegration (Figure 4.4C). For CPV-2 capsids incubated with bis-ANS, 
empty capsids displayed a slight increase in binding between 25 and 35°C, then a 
significant decrease between 35 and 55°C. These changes were not observed for full 
capsids. Above 68°C there was a dramatic increase of bin-ANS binding to both full 
and empty capsids as they disintegrated (Figure 4.4D).  The observed change between 
20 and 55°C for empty capsids was attributed to capsid structural changes, as no 
change of bis-ANS binding to the BSA control occurred over that temperature range 
(data not shown). 
Figure 4.3. 
Temperature sensitivity of CPV and related host range mutants to proteolysis. 
Susceptibilities of full capsids of CPV-2, FPV, CPV-2a, or mutants of those viruses to 
proteinase K for 2 h at the temperatures indicated.  Gels were stained with Coomassie 
blue.  Size standards are in kDa.  Controls include virus incubated without proteinase, 
fresh proteinase K, or enzyme incubated for 2 h or 37°C.  Additional bands seen at in 
the CPV-2 S297A and FPV S297A samples, or those that differ between CPV-2 and 
CPV-2 A300D, are indicated by open arrows.
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Figure 4.4. 
Temperature dependence of tryptophan fluorescence and bis-ANS binding to CPV. 
Trp fluorescence spectra of CPV-2 empty (A) and full (B) capsids at varying 
temperatures, excited at 295 nm with emission scanned between 310 and 400 nm. 
C) Trp fluorescence of full and empty CPV-2 particles as temperatures were raised at 
0.5°C/min, monitoring emission fluorescence at 331 nm.  Data is the mean of three 
independent experiments ±1 SD. 
D) Fluorescence of bis-ANS incubated with CPV-2 full or empty capsids at varying 
temperatures.  Samples were excited at 395 the emission read at 500 nm, as 
temperatures were raised at 0.5°C/min.  Data is the mean of the three independent 
experiments ±1 SD.
166 
  
167 
 Effects of pH or EGTA treatment on virus structure.  CPV-2 capsids were 
incubated with proteinase K at 37°C for 2 h in pH 7, 6, 5, and 4 buffers.  No 
significant differences in either protease susceptibility or proteolytic peptide patterns 
were seen between pHs 7.5 and 5.0, however some alternative cleavages occurred at 
pH 4 (Figure 4.5A).  Trp fluorescence spectroscopy showed no changes in the spectra 
at any of the pHs tested (Figure 4.5B), although the intensity progressively decreased 
over the pH range.  This indicates no major change in the structure, but that minor. 
changes such as a relaxation of the capsid structure likely occurred.  Binding of bis-
ANS increased greatly at low pH (Figure 4.5C).  The protein binding properties of bis-
ANS itself is generally believed to be pH insensitive (13, 46), although increased 
binding to positively charged groups can occur at lower pH (22).  The bis-ANS 
binding to BSA increased slightly at lower pH (data not shown), but the effect was 
considerably less than seen for CPV capsids, indicating that the increased fluorescence 
from bis-ANS at lower pH resulted from structural changes to the virus. 
Proteinase K treatment of CPV-2 capsids incubated with 0, 1, 10, or 50 mM 
EGTA showed no changes in the digestion levels or peptide patterns (Figure 4.6A), or 
in the emission wavelength of the Trp fluorescence spectra (Figure 4.6B).  Trp 
fluorescence intensity decreased slightly after initial EGTA treatment, indicating small 
changes in the local environment of some Trp residues.  Binding of bis-ANS to empty 
capsids gave an increase in intensity at higher concentrations of EGTA that was not 
seen for full capsids (Figure 4.6C).  Control binding to BSA did not change under 
those conditions (data not shown).   
Effects of ligand binding on capsid structure.  Incubating full CPV-2 capsids with 
Fab F or 15, or purified feline TfR ectodomain did not change the virus susceptibility 
to proteinase K (Figure 4.7A and 4.7B).  TfR itself bound very high levels of bis-ANS 
compared to capsids, and adding bis-ANS to mixtures of CPV-2 capsids and TfR
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 Figure 4.5. 
Effect of low pH on virion stability. 
A) Protein composition of CPV-2 capsids incubated with proteinase K for 2 h in the 
pH buffers indicated.  Controls include proteinase K incubated alone for 0 or 2 h, or 
capsids incubated without proteinase K. 
B) Trp fluorescence of CPV-2 full capsids at the pHs indicated. 
C) bis-ANS fluorescence of full or empty capsids at various pHs.  The dye was added 
to capsids in the cuvette, and the pH adjusted by the addition of 0.1N HCl.  Data is the 
mean of the three independent experiments ±1 SD.
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 Figure 4.6. 
Effect of calcium removal from CPV virions. 
A) CPV-2 full capsids incubated with proteinase K in the presence of various 
concentrations of EGTA.  Controls include capsids incubated with neither protease or 
EGTA, or protease incubated with 0 or 50 mM of EGTA. 
B) Trp fluorescence of full capsids in the presence of varying amounts of EGTA. 
C) The relative bis-ANS fluorescence of CPV full and empty capsids incubated with 
varying amounts of EGTA ±1 SD.
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Figure 4.7. 
The effects of the feline TfR ectodomain or antibody Fabs on the CPV-2 full virus 
capsid structure. 
A) CPV-2 full capsids incubated with the purified feline TfR ectodomain, with or 
without proteinase K treatment.  The SDS-PAGE gel was stained with Coomassie 
blue.   
B) Same as for (A), but capsids were incubated with Fabs of MAb 15 or 8.   
C) Binding of bis-ANS to full CPV-2 capsids alone, to the feline TfR alone, or the 
mixture of the two.  Results are from 3 separate experiments ±1 SD. 
D) Binding of bis-ANS to full CPV-2 capsids alone, to Fab F or Fab 15 alone, or to 
capsid-Fab mixtures. 
The fluorescent results for (C) and (D) cannot be compared directly as the TfR 
ectodomain bound the dye to much higher levels than the Fabs, so that the 
photomultiplier was at different settings for each experiment.
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 resulted in a slight decrease in bis-ANS fluorescence (Figure 4.7C).  Fab 15 and Fab F 
bound similar levels of bis-ANS as CPV, and adding the dye to pre-incubated Fab 15 
and CPV resulted in a decrease in bis-ANS fluorescence, compared to CPV and Fab 
15 alone (Figure 4.7D).  Binding of bis-ANS to CPV and Fab F gave a slight increase 
in fluorescence as compared to the binding to CPV or Fab F individually, suggesting a 
small change in the structure of one of the components upon ligand binding (Figure 
4.7D). 
Exposure of viral DNA upon heating.  The viral DNA in full CPV-2 capsids 
became accessible to TOTO-1 dye starting at ~50°C, exposure increased up to 65°C 
and showed a large increase around 70°C (Figure 4.8). No significant effect of low pH 
was seen on DNA exposure in that assay.  Digestion of heated particles with 
micrococcal nuclease reduced the DNA signal, indicating DNA externalization 
occurred, as opposed to dye entering the capsids (data not shown). 
Transmission electron microscopy and stain penetration.  The permeability 
of the capsids was examined using NanoW and NiSO4.  At 21°C NiSO4 readily 
entered empty capsids, while NanoW was largely excluded (Figure 4.9).  When 
NanoW was incubated with heat treated empty CPV capsids, penetration increased 
from 12% at 21°C, to 39% at 37°C, and 79% at 55°C, while at 75°C the particles 
disassembled.  EGTA treatment did not change the staining of empty capsids by 
NanoW (Figure 4.9C). 
 
4.5 Discussion. 
 This study confirmed that the CPV capsid is very stable, and showed that 
subtle changes occur in overall capsid structure, dynamics, and permeability.  Some 
changes appeared to be localized with respect to capsid architecture and may involve 
only a subset of capsid subunits.  The capsid responses to increased temperatures 
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 Figure 4.8. 
Staining of the DNA of CPV-2 full capsids with TOTO-1 after heating at various pHs.  
Capsids were heated for 10 mins, cooled to 21°C, dye added, and the fluorescence 
determined.  There was no statistically significant difference between the exposure of 
the DNA at any of the pHs tested.  
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 Figure 4.9. 
Permeability of CPV full and empty particles to negative stains. 
A) Negative staining of CPV-2 full or empty capsids (as indicated) with NiSO4 or 
nanoW.   
B) Negative staining of CPV-2 empty capsids with NanoW after heating to various 
temperatures for 10 mins.  
C) Negative staining of CPV-2 empty capsids with NanoW in the presence or absence 
of 10 mM EGTA.
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 provided evidence of coordinated changes in the capsid, in particular by higher DNA 
exposure of full capsids, and by reduced bis-ANS binding and increased NanoW 
penetration of empty capsids.  However, proteinase K treatments showed only small 
increases in overall capsid sensitivity, although a higher proportion of VP2 was 
cleaved to VP3 in full capsids, likely due to more ready transport of the VP2 N-
termini to the outside of the capsid through the fivefold pore. 
 The full and empty capsids were indistinguishable by Trp fluorescence, despite 
the known interactions of the DNA with the interior of the full capsid (59).  The 14 
Trp residues in the VP1/VP2 common region are mostly buried within the structure, 
and therefore would report predominantly changes to the overall capsid conformation 
(29).  Studies of VP2-only MVM virus-like particles showed changes in Trp emission 
intensity when heated between 40 and 55°C (7), but those could not be detected in our 
studies.  This could therefore reflect structural differences between the capsids of 
MVM and CPV, or between the VP2-only capsids examined in that study and the 
VP1/VP2 CPV particles examined here.  The bis-ANS binds to exposed hydrophobic 
regions of the capsid and can indicate structural changes (46). Our results show a clear 
difference in bis-ANS binding between the empty and full capsids, and those could 
reflect the differences in stability reported for full and empty MVM capsids (6), or to 
the dye entering the empty but not full capsids.  The full and empty capsids did, 
however, disintegrate at the same temperature. 
 VP2 cleavage to VP3, as well as low pH treatment, has been reported to alter 
exposure of the VP1 N-terminus in MVM (11, 26, 44). Here we saw little effect of 
lower pH on the CPV structure, with the main change in proteinase K cleavages only 
at pH 4.0, while viral DNA exposure to TOTO-1 was not affected by low pH.  We 
previously showed using X ray crystallography that at pH 6.2 or 5.5 there was reduced 
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Ca2+ bound and small changes in the arrangements of surface loops of the capsids 
(43).   
 Triggers activating capsids or envelope proteins of other viruses for infection 
include exposure to low pH, removal of bound ions, and/or protease digestion (27, 47).  
In studies of adeno-associated virus capsids or those of other viruses, uniform 
cleavages of the capsid protein(s) was seen after trypsin treatment (54).  The CPV-
related viruses replicate in the lymphoid tissues and in the small intestinal epithelial 
cells, and viruses are shed in the feces of infected animals. Thus, the virus must resist 
digestive proteases and proteolytic enzymes produced by the intestinal flora.  For CPV 
and FPV even broad-specificity proteases cleaved only a small proportion of the 
capsid subunits at select positions.  The structures of CPV-2 and FPV differ in the 
inter- or intra-chain bonds of VP2 residues 93 and 323 (15), and in the numbers of 
bound Ca2+ ions (120 or 180, depending on the virus) (45).  The CPV-2a/b capsids 
also vary from CPV-2 at VP2 residues 87, 101, 300, and 305, but showed no 
differences in the peptides generated after proteinase K digestion.   
 The Ser to Ala change of VP2 residue 297 which emerged in the CPV-2a/b-
derived virus background after 1990 (36) gave an additional sub-molar fragment when 
present in CPV-2 and FPV capsids, but not when present in CPV-2b (Figure 4.3 and 
4.10).  Several capsid protein changes near residue 297 affect binding to the canine 
TfR and to some antibodies.  The changes involved include Gly300 which likely 
increases the flexibility of the loop, and Asp300 (in CPV-2a) which would reduce its 
flexibility through the formation of new hydrogen bonds in the structure (Figure 4.10A 
and 4.10B).  The differences in the loop and surrounding structures were likely 
reflected in the loss of the 23 kDa peptide in the 300 Asp mutant (19, 23, 34).  A 
consequence of this cleavage of the surface loop of the capsid would be that the 
particles would now contain a small number of positions with a different surface 
 Figure 4.10. 
The positions of one of the protease cleavage sites in the structure of the capsid, and 
the protein or capsid relationships to the known antibody and receptor binding sites.   
A and B)  Comparison of the structures of 300Ala (A) found in CPV-2 and the 
300Asp (B) variant, showing the differences in the bonding and likely flexibility of the 
loops involved. Residue 297 is shown as a Ser, and when this is changed to an Ala in 
FPV or CPV-2 an additional submolar cleavage can occur (Figure 4.3).  The four 
loops shown are those that make up the region of the capsid surface around VP2 
residue 300.  Colors indicate the 3 different VP2 molecules involved, and numbers 
indicate the VP2 residues involved in hydrogen bonding in this region.  The submolar 
cleavage of the loop around residue 300 is controlled by the presence of Ala300 in 
CPV-2 which allows cleavage, while 300Asp is not cleaved.   
C) The location of the VP2 residues 297 and 300 on the capsid surface, relative to 
known TfR and antibody binding sites.  The three VP2 molecules that surround the 
cleavage site are colored.  The triangle indicates one asymmetric unit of the viral 
capsid.  The binding footprints of 3 different antibodies (white lines) or of the feline 
TfR (magenta) on the capsid surface are shown, to indicate the relationship of the 
cleaved loop to the binding sites of those ligands.
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 structure and charge.  That cleavage is within the footprint of many antibody binding 
sites, and closely adjacent to the TfR binding site on the capsid (Figure 4.10C).   
 We have shown that feline TfR bound to only a small number of sites on the 
CPV-2 capsid (16).  Possible explanations include intrinsic asymmetry of capsid sites 
controlling TfR binding, or changes in capsid morphology induced after TfR binding 
that prevent the attachment of additional TfRs.  In these studies no changes were seen 
in the capsid structure after TfR binding.  Sources of pre-existing asymmetry in full 
capsids could include the exposed 5’-end of the viral DNA, variable number of 
exposed VP2 or VP3 N-termini, and the 5-6 copies of VP1. 
Here we show that purified full and empty capsids also incorporate about 1-3 
copies per virion of a 70 kDa capsid protein variant that is likely a shorter form of 
VP1, and a VP2 cleaved at a single site.  The 70 kDa protein may represent a minor 
capsid protein form, perhaps similar to the VP2 protein of the adeno-associated 
viruses, or to the intermediate size minor capsid proteins of bovine parvovirus and 
minute virus of canines (42, 51).  Another source of asymmetry would also be the 
introduction of cleavages of loops within the capsid surface through specific protease 
cleavage, and in many cases those could interfere with binding of either receptor and 
antibodies, or of both ligands (Figure 4.10). 
 These results show that the capsid of the parvoviruses undergoes subtle 
changes upon heating which are associated with the permeability of the capsids but 
which do not dramatically alter the structure, and this was particularly true for the 
infectious DNA-containing capsids.  More physiological treatments such as low pH, 
removal of Ca2+, or binding of receptor of antibodies showed few changes in our 
assays, suggesting that those may act as triggers, but that dramatic changes are not 
likely to be present.  This emphasizes the likely role of changes in permeability that 
release internal components such as the viral DNA and the N-terminus of VP1.  The 
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 presence of such exposed components and also of the very low copy number protein 
forms also suggests new sources of asymmetry which may be involved in the 
functions of the capsids, and we are examining these effects in our future studies.   
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CHAPTER FIVE 
Summary and conclusions 
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The studies reported in this thesis had two main objectives: To better 
characterize the capsid interactions with antibodies of the host immune system, and to 
biochemically characterize the changes that might occur in the capsid structure during 
infection.  The first studies demonstrated that antibodies make complex interactions 
even with these structurally simple viruses, and suggested that as IgGs, these 
antibodies neutralize CPV by cross-linking capsids together, and to a lesser extent by 
steric hindrance of the capsid interaction with the TfR.  However, neither of these 
mechanisms completely explains the results presented.  It is likely that other 
mechanisms contribute to neutralization of CPV by these antibodies, such as steric 
hindrance of asymmetric sites on the CPV capsid by the highly neutralizing 
antibodies, as described below.  The studies of capsid stability demonstrate that CPV 
is extremely stable under many conditions, but that small changes can be identified 
and those are likely of biological relevance. 
Due to its structural and genetic simplicity, CPV and the related host range 
mutants are particularly good models for studying the basic properties of virus-host 
interactions.  CPV capsids can be produced in large quantities, and the genome is 
amenable to mutation.  These viruses use TfR to bind and enter cells, and this receptor 
normally enters cells using one of the better characterized endocytic pathways.  A 
number of high resolution structures of wildtype CPV and related viruses and mutants 
have been determined under various conditions.  Finally, a large number of 
monoclonal antibodies have been prepared against the capsids and those are available 
for study. 
Viruses of vertebrates make extensive interactions with the host immune 
system during infection, and part of this immune response is the production of anti-
viral antibodies that in many cases prevent or mitigate viral infection.  In this thesis, I 
have further characterized a selected panel of eight monoclonal antibodies, and 
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determined their interactions with CPV and FPV.  I have shown that all eight of these 
intact IgG antibodies are able to neutralize the virus, but that only three of the Fab 
fragments of these antibodies were able to do so.  Since these IgGs cannot bivalently 
bind the virus, the IgGs likely neutralize CPV through cross-linking of capsids, and 
also through the increased avidity that comes from the multiple interactions of the 
IgGs with the capsids.  Furthermore, the increased mass of the intact IgG compared to 
the Fab may allow it to block access to residues that are not in its own specific 
epitope.  The two highly neutralizing Fabs that neutralize the virus do so at ratios of 
<100 Fabs per capsid, while the other Fabs do not neutralize at ratios as high as ~2000 
Fabs per capsid.  In our solid phase binding assays, all of these Fabs bound with about 
the same relative affinity, suggesting that neutralization is a special property of the 
antibodies beyond just binding and blocking receptor attachment.  From our structural 
studies, the neutralizing Fabs do not bind to drastically different regions of the capsid 
compared to the non-neutralizing Fabs, although in some cases their angle of binding 
is more skewed across the two-fold axis than other antibodies. 
There are several possibilities that could explain the difference for 
neutralization abilities between these Fabs.  It is possible that these neutralizing Fabs 
interact with capsids in a way that the non-neutralizing Fabs do not. We did not 
observe any conformational changes in the Fab-CPV reconstructions and by 
biochemical analysis, indicating that Fab binding did not induce detectable 
pronounced changes in the virus.  The possibility of structural asymmetry in CPV has 
been raised recently, since TfR binds CPV capsids with low occupancy, despite an 
excess of TfR added in those experiments.  It has therefore been suggested that there 
may be a small number of “special” sites on the virus that TfR but not antibodies bind 
to.  In this model, the neutralizing Fabs leaning across the two-fold axis would 
sterically interfere with receptor binding, while the non-neutralizing Fabs would be 
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less able to compete, despite a large number of Fabs bound.  Fabs missing from a few 
vertices on the virus would not be seen in the cryoEM reconstructions, since sixty fold 
icosahedral averaging was used to solve those structures.  Since the neutralizing Fabs 
are skewed across the two fold axis, they may block TfR binding to these adjacent 
special sites.  This model is supported by the fact that TfR binds with low occupancy 
to capsids, the two neutralizing Fabs compete with TfR binding at lower Fab to capsid 
ratios, and that the non-neutralizing Fabs do not block infectivity at high molar ratios 
of Fabs to CPV.  However, all of the Fabs studied are able to compete with receptor 
binding to some degree.  This indicates that receptor binding may require some 
interaction with residues outside of these special sites, or regions of TfR protrude 
away from these special sites and clash with other, non-neutralizing antibodies.  
However, since these antibodies do not neutralize CPV, this interaction would clearly 
be less effective than these which occlude the asymmetric position on CPV. 
A second possibility that may explain the differing ability of these Fabs to 
neutralize virus could be related to subtle differences in their binding abilities.  For the 
competition experiments of Fabs and TfR binding of the capsids in in vitro binding 
assays and on cells, the virus and antibody were incubated for one hour at 37°C, and 
then overlaid onto cells or plates for 1 h.  The unbound virus was washed away and 
measurements taken.  Conversely, for the neutralization experiments, virus and 
antibody were mixed for 1h at 37°C, then incubated with cells for 48 h. Since TfR 
endocytosis is such a rapid event, any virus that disengages an antibody and binds to 
receptor would be expected to be rapidly taken up into cells.  Therefore, small 
differences between the off rates of these Fabs could result in differences in 
neutralization that were not seen in the competition experiments, since the time 
interval during the neutralization experiments was much greater.  However, the non-
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neutralizing Fabs do not decrease infectivity at high antibody concentrations, and this 
would be expected if binding kinetics were the sole explanation for neutralization. 
Clearly, more work needs to be done to resolve these issues, and several areas 
of future research will hopefully identify mechanisms of neutralization of CPV by 
antibodies.  First, an accurate measurement of the binding affinities and kinetics of 
Fabs and TfR for CPV and their related host range mutants is critical.  The use of 
surface plasmon resonance would be ideal, since this would allow measurement not 
only of affinity, but also on and off rates.  Analytical ultracentrifugation of CPV and 
TfR pre-incubated with concentrations of TfR well above the dissociation constant 
would be useful for determining stoichiometry of binding.  Unfortunately, it would be 
difficult to demonstrate the absence one or two antibodies on the CPV capsid by 
analytical ultracentrifugation.  Further characterization of these special sites, and their 
interactions with CPV and TfR would be critical.  For example, it is possible that 
clustering of VP1 molecules around one vertex is responsible for asymmetry in CPV.  
Studies involving chemical cross-linking of the capsid could help to resolve 
distribution of VP1; VP1 has been shown to preferentially cross-link in the related 
parvovirus H-1, and may be a more general trend in the Parvoviridae family.  
Alternative approaches, such site-directed spin labeling in the N-terminus of VP1 and 
detection with electron paramagnetic resonance spectroscopy or double electron-
electron resonance would help to localize distances between VP1 N-termini.  These 
methods have been used extensively to determine distances between specific residues 
in other proteins. 
The shared binding footprints of the eight Fabs overlap the areas that are sites 
where escape mutations are found; however, the distinctions between the A and B 
sites are not as clear as previously thought.  The combined footprints of these eight 
antibodies cover most of the accessible surface of the virus.  As a future study, I would 
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propose immunizing mice with capsids containing escape mutation substitutions in 
both site A and B, and cleaved N-termini of VP2, to see whether other sites on the 
virus could serve as functional epitopes in the absence of the major antigenic sites, and 
whether these antibodies are neutralizing.  I also propose to sequence the variable 
domains of more of the monoclonal antibody library against CPV.  These sequences 
could then be used to characterize what gene segments preferentially contribute to 
anti-CPV antibody selection in mice.  It would be interesting to see whether these 
antigenically altered viruses promoted the use of other antibody gene segments during 
selection of reactive B cells.  Finally, all of the virus-Fab structures solved so far 
involve high affinity IgGs, and it would be interesting to examine the low affinity IgM 
antibodies that are produced early in the response to see if those also bind around the 
two antigenically variable A and B structures of the capsid.  These proposed studies 
will hopefully provide a mechanistic understanding into the viral structures that 
determine the selection and maturation of antiviral antibodies. 
The second aim of this thesis was to examine the effects on the virus capsid 
structure of various conditions that CPV encounters during endocytic uptake and 
release from endosomes.  Since CPV binds TfR, is trafficked through recycling and/or 
late endosomes, I focused on the effects of receptor binding, low pH, and calcium 
removal on the capsid.  Low pH had little pronounced structural effect on CPV, which 
is consistent with X-ray diffraction data.  Intrinsic tryptophan fluorescence showed 
that the hydrophobic environment of the Trp residues was not significantly altered at 
lower pH, although the fluorescence intensity was reduced, indicating that these 
residues may be more flexible and that they are partially quenched in the capsid at 
lower pH.  Binding of the hydrophobic dye bis-ANS to CPV capsids and also studies 
using limited proteolysis with proteinase K both showed that the surface structure of 
this virus is unchanged until ~pH 4.  In addition, release of viral DNA was not pH 
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dependant, indicating that other factors are important in its release.  These results are 
consistent with structural data, which showed that only small changes in some surface 
loops at pH 6.2.  Low pH in the endosome is necessary for CPV infection, but at this 
point the role of low pH is not understood - whether this is due to a direct effect of pH 
on the capsid or receptor structure, or to some other role of low pH in the viral 
infectious process, or perhaps the low pH causes capsid changes that are not detectable 
in these assays, is not known. 
Calcium removal also does not cause large conformational changes to the 
structure of full particles in solution by limited proteolysis, tryptophan fluorescence, 
and bis-ANS binding.  Empty particles do show increased binding of bis-ANS under 
EGTA treatments, but is unclear whether this occurred on the surface of capsids, or 
(more likely) that the bis-ANS more readily gains access to the interior of the empty 
capsids compared to the full particles.  This again is consistent with the structural data, 
where only small changes are seen at high EGTA concentrations. 
I showed that TfR binding to CPV capsids did not cause global conformational 
changes detectable by bis-ANS binding or limited proteolysis.  Previously, we had 
shown that TfR binds CPV with low occupancy despite a molar excess of TfR, and 
had hypothesized that this occurred because of conformational changes to the virus, or 
due to a low number of potential binding sites present on the virus.  In light of the 
work presented here, it appears more likely that inherent asymmetry in CPV is a more 
plausible explanation for this phenomenon. 
What changes to the CPV capsid are actually required for infection?  As 
demonstrated in this presented work, it appears large conformational changes do not 
occur in the capsid under conditions encountered during infection.  This therefore is 
quite a different result from those reported for many other viruses where the viral 
proteins or capsids undergo major uniform changes in conformation at low pH, after 
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proteinase cleavage or ion removal.  At the very least however, the 3’ end of the viral 
ssDNA genome needs to become exposed to engage host polymerases.  The capsids 
must also deploy some membrane-lytic or modifying structure to allow escape from 
endosomes.  The PLA2 domain of VP1ur may fulfill this role.  Specific assays should 
be designed to identify the physiological factors that cause VP1ur externalization.  
Furthermore, an understanding of how the PLA2 activity modifies endosomal 
membranes to promote infection is critical.  Understanding the mechanisms and 
structural controls of release of the VP1ur would also be important, and might be 
facilitated by the generation of pseudo atomic structures on heated virions that have 
exposed their VP1ur.  These studies may also help to identify whether the VP1ur is 
released from one specific region on the capsid with respect to TfR binding or ssDNA 
release, or is randomly distributed.  Heating to 60°C causes not only externalization 
the VP1ur, but also part of the ssDNA genome.  Cryo-EM and image reconstructions 
would therefore also be able to visualize these transitioned particles, and would help 
explain the relationship between DNA and VP1ur release.  Also, if TfR binding and 
VP1ur release are similarly arranged, this may act to orient the release of their PLA2 
towards the endosomal membrane.  Similar studies have been done in poliovirus, 
which appears to release its RNA through a pore in the endosomal membrane 
surrounded by poliovirus receptor molecules, and presumably the externalized VP4 
molecules. 
I also showed that some mutations in a region of the capsid around VP2 
residue 300 determine it protease sensitivity.  The A300D substitution forms an 
additional stabilizing hydrogen bond, which would cause surface loop 3 to be less 
flexible in solution, and this loop is then not cleaved by proteinase K. There are no 
large structural differences between CPV and FPV, but those viruses differ in their 
ability to bind canine TfR.  It is therefore possible that flexibility of the loop 
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containing residue 300 is determining differences in host range, since this A300D 
substitution (and the structurally related VP2 residue 299 change from Gly to Glu) 
results in less infectivity in canine cells through alterations in canine TfR binding.  
Several avenues of research could address this issue.  First, high resolution structures 
of the CPV-TfR complex should be generated.  This will allow us to determine 
whether the capsid substitutions that control host range directly control the interactions 
with the TfR.  If no direct interaction is shown, then binding to TfR may be controlled 
by flexibility of this loop.  Introduction of cysteine residues in this flexible loop could 
allow us to specifically control flexibility through the formation of disulfide bonds, 
and allow us to assay the ability of these capsids to bind TfR.  This will help to further 
understand the fine tuning of the CPV-TfR interaction. 
Finally, I identified three proteins that are incorporated into the capsid at a low 
molar ratio compared to VP1 or VP2.  Two of these proteins correspond to a VP2 that 
is cleaved in one position.  Mass spectrometry and Western blotting with anti-peptide 
anti-sera predicts that this cleavage occurs between residues 280-290.  Interestingly, 
none of the proteases used in these experiments generated a similar cleavage in the 
capsids.  The other identified protein (about 70kDa) likely corresponds to a lower 
molecular variant of VP1 and may be the result of alternate splicing of the VP1 
mRNA.  Future studies should continue to characterize these proteins and to explain 
their roles (if any) in the viral life cycle.  For the cleaved VP2, residues involved in 
this cleavage should be identified and mutants at that position prepared and assayed 
for their infectivity and stability.  Since this cleavage most likely occurs after capsid 
assembly, the protease or other host (or viral) factor that is responsible for this 
cleavage should be identified and knocked out or inhibited to determine its effect on 
viral infectivity.  If the higher molecular weight peptide is indeed a splice variant of 
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VP1, then the acceptor/donor sequences of that splice could be mutated and the effect 
on infectivity should be determined. 
This thesis has increased our understanding of the interactions that CPV makes 
with antibodies, receptors, and other host factors during viral infection.  The methods 
developed and presented in this thesis are tractable and can readily be adapted to 
address other questions involving antibody-virus interactions and structural changes to 
viral capsids. 
